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Abstract
Pretzel Syndrome (also Polyhydramnios, Megalencephaly, and Symptomatic Epilepsy syndrome; PMSE) is
a recently described rare neurodevelopmental disorder occurring in the Old Order Mennonite pediatric
population, and characterized by intractable infantile-onset epilepsy, neurocognitive delay, craniofacial
dysmorphism, and histopathological evidence of heterotopic neurons in subcortical white matter,
suggestive of failed neuronal migration. PMSE is caused by a homozygous deletion of exons 9-13 of
LYK5/STRADA, which encodes the pseudokinase STRADA, an upstream inhibitor of mammalian target of
rapamycin (mTOR). Therefore, we hypothesize that STRADA plays a critical role in neuronal migration
through modulating mTOR (specifically mTOR complex 1, mTORC1) signaling, and that therapeutic
mTORC1 inhibition can ameliorate features of the PMSE disease phenotype. To test this hypothesis, we
model PMSE in vitro using stable shRNA knockdown of STRADA (STRADA KD) in mouse neural progenitor
cells (mNPCs). In vivo, we use in utero electroporation to create focal STRADA KD in the developing
mouse brain. We show that STRADA depletion disrupts pathfinding and polarization in migrating mNPCs
in vitro, and this effect can be rescued by inhibition of mTORC1 with rapamycin or of its downstream
effector p70S6kinase (p70S6K) with PF-4708671 (p70S6Ki), indicating an mTORC1-specific dependence.
We then define a pathway for this effect downstream of mTORC1, through insulin receptor substrate 1
(IRS1) signaling to cofilin, and finally modulating actin dynamics. In vivo, we demonstrate that STRADA KD
causes a cortical lamination defect in the mouse, which can be rescued with rapamycin treatment,
confirming the dependence of STRADA's effect on mTORC1 signaling and suggesting an important target
for patient therapy. To correlate our mouse model with PMSE, we demonstrate congruent mTORC1 and
downstream signaling and rescue of migration deficit with rapamycin and p70S6Ki in PMSE patient
fibroblasts. Finally, we report reduction of seizure frequency with rapamycin treatment in previously
intractable PMSE patients. Our findings define a novel role for STRADA in neuronal migration,
demonstrate a mechanistic link between STRADA loss and mTORC1 hyperactivity in PMSE, and suggest
that mTORC1 inhibition can serve as an effective therapeutic bio-target in PMSE as well as other
devastating mTOR-associated neurodevelopmental disorders.
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ABSTRACT
INSIGHTS FROM PRETZEL SYNDROME: THE ROLE OF STRADA IN
NEURONAL MIGRATION AND CORTICAL DEVELOPMENT
Whitney E. Parker
Peter B. Crino, M.D., Ph.D.
Pretzel Syndrome (also Polyhydramnios, Megalencephaly, and Symptomatic Epilepsy
syndrome; PMSE) is a recently described rare neurodevelopmental disorder occurring in
the Old Order Mennonite pediatric population, and characterized by intractable infantileonset epilepsy, neurocognitive delay, craniofacial dysmorphism, and histopathological
evidence of heterotopic neurons in subcortical white matter, suggestive of failed neuronal
migration. PMSE is caused by a homozygous deletion of exons 9-13 of LYK5/STRADA,
which encodes the pseudokinase STRADA, an upstream inhibitor of mammalian target of
rapamycin (mTOR). Therefore, we hypothesize that STRADA plays a critical role in
neuronal migration through modulating mTOR (specifically mTOR complex 1,
mTORC1) signaling, and that therapeutic mTORC1 inhibition can ameliorate features of
the PMSE disease phenotype. To test this hypothesis, we model PMSE in vitro using
stable shRNA knockdown of STRADA (STRADA KD) in mouse neural progenitor cells
(mNPCs). In vivo, we use in utero electroporation to create focal STRADA KD in the
developing mouse brain. We show that STRADA depletion disrupts pathfinding and
polarization in migrating mNPCs in vitro, and this effect can be rescued by inhibition of
mTORC1 with rapamycin or of its downstream effector p70S6kinase (p70S6K) with PF4708671 (p70S6Ki), indicating an mTORC1-specific dependence. We then define a
iv

pathway for this effect downstream of mTORC1, through insulin receptor substrate 1
(IRS1) signaling to cofilin, and finally modulating actin dynamics. In vivo, we
demonstrate that STRADA KD causes a cortical lamination defect in the mouse, which
can be rescued with rapamycin treatment, confirming the dependence of STRADA’s
effect on mTORC1 signaling and suggesting an important target for patient therapy. To
correlate our mouse model with PMSE, we demonstrate congruent mTORC1 and
downstream signaling and rescue of migration deficit with rapamycin and p70S6Ki in
PMSE patient fibroblasts. Finally, we report reduction of seizure frequency with
rapamycin treatment in previously intractable PMSE patients. Our findings define a novel
role for STRADA in neuronal migration, demonstrate a mechanistic link between
STRADA loss and mTORC1 hyperactivity in PMSE, and suggest that mTORC1
inhibition can serve as an effective therapeutic bio-target in PMSE as well as other
devastating mTOR-associated neurodevelopmental disorders.
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INTRODUCTION1
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Figures in this chapter are adapted from images originally published in The Journal of
Clinical Investigation, Vol. 120, No. 5, May 2010. Orlova, K.A., Parker, W.E., Heuer,
G.G., Tsai, V., Yoon, J., Baybis, M., Fenning, R.S., Strauss, K., and Crino, P.B.
STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in
humans in mice.
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STRAD Structure and Classification
STe20-Related ADaptor (STRAD) was first identified in a yeast 2 hybrid screen
of a fetal brain library, as a binding partner of the tumor suppressor protein
serine/threonine kinase 11 (STK11, also known as liver kinase B1, LKB1) (1). Its
sequence most closely resembles the STE20 homologues SPAK and ILPIP or PAP kinase
(1-4). Unlike these homologous kinases, however, STRAD lacks residues indispensable
for intrinsic catalysis (phosphoryl transfer), and is thus categorized as a pseudokinase.
Specifically, it lacks the DFG motif for magnesium interaction in the ATP-binding cleft
and harbors a serine replacement of the aspartic acid residue critical for mediating proton
transfer in the catalytic site (1, 5).

As a consequence, STRAD remains unable to

autophosphorylate or to phosphorylate any of a number of substrates tested in in vitro
kinase assays (1). Interestingly, much like a kinase, STRAD can adopt an “active” closed
conformation, stabilized through association with ATP or binding partner mouse protein
25 (MO25) (5). This has led to speculation that STRAD may have evolved from a kinase
capable of catalysis (6).
Cellular Role of STRAD as a Pseudokinase
Prompted by STRAD’s discovery as an LKB1-binding partner, Baas et al. chose
to investigate this interaction. Co-immunoprecipitation experiments with mutant strains
of LKB1 revealed that the entire kinase domain as well as C-terminal amino acid residues
319-343 are essential for LKB1 to bind the pseudokinase domain of STRAD (1). This
interaction results in activating autophosphorylation of LKB1 at at least four sites
including Thr336, Thr363, Thr185, and Thr402, as well as phosphorylation of STRAD at
2

Thr329 and Thr419 by LKB1 (1). Kinase assays measuring the phosphorylation of
myelin basic protein (MBP), a non-specific LKB1 substrate, as an indicator of LKB1
catalysis revealed that STRAD binding enhances LKB1 activity approximately 4-fold (7).
Additionally, STRAD translocates LKB1 from nucleus to cytoplasm (1). Dorfman et al.
have shown that STRAD accomplishes LKB1 cytoplasmic localization by serving as an
adapter between LKB1 and nuclear export proteins chromosomal region maintenance 1
(CRM1) and exportin7 and by serving as a competitive inhibitor to importin-α binding
LKB1 (8). Localization in the cytoplasm is crucial for several of LKB1’s functions,
including growth arrest (9), G1 cell cycle arrest (1), neuronal axon specification (10, 11),
and modulation of mTORC1 signaling (12).

This was confirmed through a study

demonstrating that an exclusively cytoplasmic LKB1 mutant (lacking the nuclear
localization signal) remained able to induce cell growth arrest, while its exclusively
nuclear mutant counterpart did not (9).
The STRAD/LKB1/MO25 Complex
STRAD and LKB1 form a heterotrimeric complex with the scaffolding protein
MO25 in a 1:1:1 ratio. MO25 interacts directly with STRAD by binding to STRAD’s
last three C-terminal amino acid residues. MO25 binding enhances formation of the
STRAD-LKB1 complex, and formation of the trimer enhances LKB1’s catalytic activity
approximately 10-fold (7, 13). STRAD and MO25 each exist in alpha and beta isoforms,
with large sequence homology and considerable phenotypic overlap. STRADα/β and
MO25α/β can each participate in the formation of the heterotrimeric complex to activate
LKB1 (7, 13-15).
3

AMPK Regulation of Cell Energy
LKB1 functions as a master kinase, phosphorylating several downstream kinases,
including 13 of the AMP-activated protein kinase (AMPK) subfamily (16). AMPK is an
evolutionarily-conserved cellular energy sensor that serves to inhibit energy-consuming
metabolic pathways in the setting of increased cellular AMP/ATP ratio, by promoting
catabolic and antagonizing anabolic processes (17, 18).

LKB1 activated through

complexation with STRAD and MO25 phosphorylates AMPK at Thr172, a modification
essential to AMPK function (14, 16, 19). In fact, LKB1-deficient murine embryonic
fibroblasts (MEFs) exhibit negligible AMPK (Thr172) phosphorylation and consequent
lack of AMPK downstream signaling (19). The drug 5-aminoimidazole-4-carboxamide
riboside (AICAR) is immediately converted in cells to an AMP mimetic, which activates
AMPK by simulating low cellular energy levels (20). AICAR, as well as two additional
AMPK-stimulating drugs, metformin and phenformin, failed to activate AMPK in LKB1null MEFs or LKB1-deficient HeLa cervical cancer cells (14, 21-23). Expression of
LKB1 in either of these cell lines, however, restores AMPK sensitivity to
pharmacological activation, indicating an essential role for LKB1 in the response of
AMPK to cellular energy levels (14, 19).
mTOR Signaling
AMPK plays a key role in modulating activity of the energy-demanding
mammalian target of rapamycin (mTOR) cascade. Complexed with and activated by
STRAD and MO25, LKB1 activates AMPK. Activated AMPK phosphorylates Tuberous
Sclerosis Complex 2 (TSC2) (Thr1227, Ser1345), activating the TSC1:TSC2 complex
4

(23-26).

The TSC1:TSC2 heterodimer inactivates Ras-homolog expressed in brain

(Rheb), stimulating the conversion of Rheb-GTP to Rheb-GDP, and thereby inhibiting
mTOR kinase activity (25-30). mTOR forms two distinct complexes, mTORC1 (with
raptor) and mTORC2 (with rictor) (31) (reviewed in (32)).

Additionally, AMPK

phosphorylates raptor, modifying the mTORC1 complex and inhibiting mTORC1
through a second mechanism (33).

Notably, the macrolide antibiotic rapamycin

powerfully inhibits mTORC1 almost exclusively, with minimal effects on mTORC2
signaling after prolonged treatment (34, 35). mTORC1 regulates several key cellular
processes including cell growth, transcription, translation, ribosome biogenesis,
differentiation, autophagy, and metabolism (26).

Perhaps most notably, activated

mTORC1 directly phosphorylates ribosomal protein p70S6kinase1 (p70S6K), important
for cell growth, and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), critical for initiation of cap-dependent mRNA translation (36-39). Phosphorylation
of p70S6K1 and its substrate ribosomal S6 protein (S6) serves as an important clinical
biomarker for mTORC1 activation in neurons (40, 41).

Recent phosphoproteomic

analyses have identified several hundred mTOR-associated substrates, suggesting broad
relevance in the pathogenesis of several diseases as well as numerous therapeutic targets
(42, 43).
mTOR Dysregulation and Cortical Malformation
Enhanced mTOR activity has been shown to be associated with focal cortical
malformation (FCM) characterized by altered cortical cytoarchitecture and epilepsy in
human disease, and a similar phenotype in murine models with mutation or knockdown
5

of an mTOR inhibitor.

Four FCM subtypes, Tuberous sclerosis complex (TSC),

hemimegalencephaly (HME), ganglioglioma (GG), and focal cortical dysplasia type IIB
(FCDIIB) all express evidence of aberrant mTORC1 activation in cortex, associated with
epilepsy, suggesting a causative link (40, 44-49).
mTOR is expressed in the proliferative zones of the murine brain during early
development, and likely plays a critical role in corticogenesis (50), and its dysregulation
disrupts this process. Astrocyte-specific conditional knockout of mTOR inhibitor Tsc1 in
mice (Tsc1GFAP cKO) results in abnormal hippocampal neuronal organization,
astrocytosis, seizures, and early death (51). Similarly, conditional KO of Tsc1 in neurons
results in structural abnormality of hippocampus and cortex, associated with cytomegaly
and enhanced phosphorylated S6 (P-S6) immunohistochemical staining, as well as
seizures and early death (52). Selective KO of Tsc2 in radial glial progenitor cells results
in cortical and hippocampal lamination defects, cytomegalic dysplastic neurons and glia,
enhanced mTORC1 signaling, and early death (53). Conditional astrocytic KO of Tsc2
results in a more drastic phenotype than astrocytic KO of Tsc1, with astrogliosis,
progressive megalencephaly, more severe epilepsy, and earlier premature mortality,
associated with higher levels mTORC1 activity (54).

Interestingly, treatment with

rapamycin ameliorates disease phenotype associated with either Tsc1 or Tsc2 depletion,
implicating a causative role for enhanced mTORC1 signaling in pathogenesis (54, 55).
Phosphatase and tensin homolog detected on chromosome ten (PTEN) serves as
an upstream inhibitor of mTOR through antagonizing PI3kinase and thus, mTOR’s
response to extracellular growth signals (reviewed in (56)). Conditional neuronal Pten
6

KO in mice results in neuronal cytomegaly and macrocephaly, with enhanced mTORC1
activity and spontaneous seizures (57, 58). Importantly, as with TSC models, rapamycin
can suppress disease phenotype in Pten-deficient mice, further implicating loss of
mTORC1 inhibition as a key step in neuropathogenesis of cortical malformation and
epileptogenesis (59, 60).
PMSE, a Rare Disorder From STRADA Mutation
In 2004, researchers and physicians at the Clinic for Special Children in Lancaster
County, Pennsylvania identified a cohort of seven previously undiagnosed pediatric
patients in the Old Order Mennonite community who shared a constellation of symptoms
including macrocephaly, craniofacial dysmorphism, skeletal muscle hypoplasia,
hypotonia, and infantile-onset medically-intractable complex partial epilepsy (61). All
patients exhibited severe neurodevelopmental deficits, with projected adult mental ages
between 6 and 12 months across four developmental domains assessed with the Denver
Developmental Screening Test II. All patients were distantly related, and all parents
were asymptomatic, suggestive of a recessive inheritance pattern. Single nucleotide
polymorphism (SNP) analysis of patients produced “no calls” for the marker rs721575
located within chromosome 17. DNA sequencing and amplification within that region
revealed that all patients shared a homozygous 7304 bp deletion of exons 9-13 of
LYK5/STRADA (61). This was the first time that a STRADA mutation had been described
in a human disease. The disorder was designated Polyhydramnios, Megalencephaly, and
Symptomatic Epilepsy syndrome (PMSE), and referred to colloquially as Pretzel
Syndrome, to describe the common posturing assumed by the patients. To date, only 25
7

patients have been diagnosed with PMSE. Genotyping of healthy individuals in the Old
Order Mennonite community of Lancaster County reveals the carrier frequency of the
mutated allele to be approximately 4% within that community.
Cranial magnetic resonance imaging (MRI) studies from PMSE patients reveal
ventriculomegaly, multiple areas of high water diffusion within the white matter thought
to correspond to astrogliosis and white matter vacuolization seen on histopathological
analysis, and evidence of subependymal dysplasia (61). Analysis of a postmortem 7month old PMSE patient brain revealed enlarged neurons and areas of vacuolization
within the cerebellum, hippocampal dentate gyrus, trochlear nerve nuclei, substantia
nigra, anterior pituitary, and anterior horn of the spinal cord. Large dysmorphic cells,
reminiscent of balloon cells found in focal cortical dysplasia, were seen in frontal cortex
(61). Importantly, dysmorphic cells in both putamen and cortex were highly reactive for
P-S6, indicating enhanced mTORC1 activation (12, 61). Immunohistochemical staining
for the protein product of LYK5/STRADA, STRADA (also referred to as STRADα),
revealed a lack of protein expression in PMSE, relative to control cortex, indicating the
likelihood that the pathogenic mutation produces an unstable variant of the protein (12).
Indeed, attempted expression in 293 cells of the truncated STRADA protein (truncation
at residue 251) that serves as the product of the PMSE mutation results in negligible
protein levels.

Additionally, this variant does not bind or activate LKB1 (5).

Importantly, PMSE brain exhibits blurring of the grey-white matter junction, due to the
presence of neurons heterotopically in the subcortical white matter (Figure 1.1) (12).
This pathological characteristic is highly suggestive of failed neuronal migration, and
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primes consideration of this as a mechanism contributing to neurodevelopmental
abnormalities in PMSE and possibly other mTOR-associated disorders.
Mouse Models of PMSE
Earlier work from our lab has demonstrated that experimental models of PMSE
largely replicate disease pathology through depletion of STRADA. Stable or transient
knockdown (KD) of STRADA in mouse neural progenitor cells (mNPCs) using targeted
short-hairpin RNA (shRNA) in vitro results in cytomegaly associated with enhanced
mTORC1 signaling (Figure 1.2) (12). Importantly, treatment with rapamycin is able to
prevent these effects. Knockdown of STRADA in the embryonic day 14 (E14) mouse
brain using in utero electroporation (IUE) results in an abnormal retention of STRADAdeplete cells in the germinal center ventricular/subventricular zone (VZ/SVZ) at E17 and
E19, and failure to reach the cortical plate (CP), their appropriate destination by E19
(Figure 1.3) (12). We show that this phenotype is associated with enhanced P-S6,
indicative of aberrant mTORC1 signaling (Figure 1.4). Interestingly, we report that
depletion of STRADA in vitro and in vivo is associated with almost exclusively nuclear
localization of LKB1, consistent with a failure of LKB1 translocation from nucleus to
cytoplasm in the absence of STRADA (Figures 1.4, 1.5) (8, 12). This effect is replicated
in PMSE patient cortex, suggesting that absence of LKB1 in the cytoplasm may
contribute to disease pathogenesis (Figure 1.6) (12).
STRADA, mTOR, and Cell Migration
Our PMSE modeling studies contribute to a growing body of evidence that
mTORC1 signaling is important for proper cortical lamination and neuronal migration
9

during brain development.

Similar to STRADA in vivo knockdown experiments,

knockdown or knockout of Tsc1 or Tsc2 in murine models of cortical development
results in a failure of Tsc-deficient neurons to reach their intended destination of CP
layers II/III, adjacent to pia (62, 63). Importantly, treatment with rapamycin results in
significant histological rescue (63, 64). LKB1 knockdown through RNA interference
(RNAi) in vivo at E14 results in a predominance of LKB1-deficient neurons abnormally
in the intermediate zone (IZ) at E16, E17, and E18, suggestive of migratory arrest (65).
Recent studies in vitro have indicated a role for mTOR signaling in fibroblast migration,
through the Rho GTPases Rac1 and Cdc42.

Tsc2-null rat embryonic fibroblasts

demonstrate impaired migration and polarity in a wound-healing scratch migration assay,
associated with reduced activation of Rac1 and Cdc42 (66).

Consistent with an

established link between mTORC1 and Rho GTPase signaling, through p70S6K
phosphorylation of the insulin receptor substrate 1 protein (IRS1), the migration
phenotype in Tsc2-deficient cells was significantly rescued through expression of
constitutively-active PI3kinase or treatment with rapamycin (66, 67). Previously, Rac1
and Cdc42 have been implicated as playing an essential role in the radial migration of
cortical neurons, possibly through establishment of appropriate cell polarity (68, 69).
STRAD-associated signaling mechanisms are intimately linked to cell polarity.
LKB1 was originally identified in a genetic screen for mutations that disrupt the zygotic
anterior-posterior axis determination (70). Downregulation of STRAD or LKB1 in vivo
in the developing murine brain results in disruption of neuronal polarization, seen as a
failure of axonal formation (10, 11). Conversely, overexpression of STRAD or LKB1
resulted in the formation of supernumerary axons. Correlatively, neurons reaching the
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CP (representing a minority of cells) in LKB1 knockdown IUE experiments exhibited
inverted apical-basal orientation, with axon-like neurites oriented toward the pia instead
of the ventricle. This effect was significantly prevented by co-transfection with an
RNAi-resistant LKB1 mutant, indicating an essential role for LKB1 in neuronal
polarization (65). These studies are reminiscent of a very compelling set of experiments
demonstrating that induced expression of STRAD in intestinal epithelial cells is sufficient
to cause cells to remodel their actin cytoskeleton to polarize and form an apical brush
border, in an LKB1-dependent manner, and independently of cell-cell contacts (71).
Given the severity of neurological disease phenotype in PMSE, the strong
association of STRADA loss with aberrant mTOR activity, and the relationship of
STRAD/LKB1 and mTOR signaling to cell polarization, we hypothesize that STRADA
plays a critical role in neuronal migration and polarity through regulating actin
dynamics. Work in our lab shows that depletion of STRADA in vitro in mNPCs results
in migration impairment in a wound-healing migration assay, in an mTORC1-/p70S6Kdependent manner. Analysis of this phenomenon on an individual-cell level, using timelapse video microscopy, reveals that STRADA knockdown causes a loss of neuronal
pathfinding capacity, without deficit in total distance translocated. This corresponds to a
disruption of mNPC polarity, which is prevented by inhibition of mTORC1 with
rapamycin or p70S6K with a novel inhibitor PF-4708671 (72).

We propose that

STRADA loss in PMSE leads to aberrant corticogenesis through impairing neuronal
polarity and pathfinding in an mTORC1- and p70S6K-dependent manner. In support of
this mechanism, rapamycin treatment rescues the cortical lamination defect associated
with STRADA KD in the developing mouse brain. Polymerized or filamentous (F) actin
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plays a critical role in establishing polarity of migrating cells (73). We demonstrate that
STRADA knockdown in mNPCs results in enhanced mTORC1 activity, inhibiting IRS1
signaling, reducing PAK1 and LIMK activation, and consequently disinhibiting cofilin,
which serves to depolymerize actin. We confirm this mechanism in STRADA-deficient
PMSE patient fibroblasts extracted from human skin-punch biopsy samples, and show
that signaling abnormalities can be rescued through inhibition of mTORC1 or p70S6K.
Immunohistochemical analysis reveals enhanced IRS1 phopshorylation in PMSE cortex,
linking STRADA/mTOR activation to downstream cofilin signaling in this disease
process in the human brain. Finally, we demonstrate that dysregulated mTORC1/IRS1
signaling associated with STRADA loss results in the functional consequence of
diminished actin polymerization, seen as an increase in the ratio of depolymerized
globular (G) to polymerized F actin, in both STRADA-deplete mNPCs and PMSE patient
fibroblasts. We propose that disruption of actin dynamics as a consequence of STRADA
loss impairs neuronal polarity and pathfinding, resulting in aberrant corticogenesis. Thus,
we add STRADA to the list of mTOR-regulatory proteins that play a critical role in
neuronal polarization and pathfinding, and submit that PMSE serves as a novel model
disorder for investigation of mechanisms responsible for the pathogenesis of focal
cortical dysplasia.
The following chapters address our investigation of the role of STRADA as well
as mTOR signaling in cortical development:
•

Chapter 2 provides a descriptive account of the expression of several growth
factors and receptors that modulate mTOR signaling, in a related canonical
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mTOR-associated neurodevelopmental disorder, TSC. This provides an initiation
to the study of mTOR dysregulation and neurological disease.
•

Chapter 3 defines the role of STRADA in cortical development as a director of
neuronal pathfinding and migration, through regulating actin dynamics.

•

Chapter 4 describes our progress in generating a STRADA knockout mouse to
model PMSE and STRADA’s role in cortical development in vivo.

•

Chapter 5 provides an overall summary of dissertation studies and their
implications for future work and clinical treatments.

Significance
mTOR cascade signaling regulates several key processes in cortical development.
Loss of any of several modulators of this signaling pathway results in aberrant
corticogenesis, and a common spectrum of clinical symptoms including epilepsy and
autism-like features. While much work has been done to define the effects of TSC1/2 or
PTEN depletion, associated with the clinical syndromes TSC and autism-macrocephaly
syndrome, respectively, relatively little is known about the newly-identified mTOR
regulator STRADA and its rare but dramatic associated clinical syndrome PMSE. We
believe that STRADA serves as an ideal model mTOR regulatory protein, and PMSE an
ideal model disorder for several reasons. First, PMSE is the only known human disorder
resulting from a homozygous mutation in an mTOR inhibitor. Second, STRADA
homozygous mutation is associated with 100% penetrance of the disease, with a severe
epileptic and neurocognitive phenotype common to all patients. Finally, all patients with
PMSE share the same STRADA deletion (61).
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It is an especially exciting time for the development of biologically-targeted
therapies, with the mTORC1 inhibitor rapamycin already showing promising results in
several clinical trials for related mTOR-associated disorders, and with the development of
other inhibitors to target nodes on the mTOR pathway, such as the p70S6kinase inhibitor
PF-4708671 and the dual mTORC1/mTORC2 inhibitor Torin1 (72, 74, 75). In our
studies, we define a novel role for the mTOR inhibitory protein STRADA in directing
migrating neurons, a function we propose to be critical in cortical development, and the
disruption of which can account for several neuropathological features of PMSE.
Importantly, we develop STRADA-depletion PMSE models as a mechanism for defining
the role of mTOR signaling in cortical development and for identifying molecular targets
for the development of novel therapeutics for mTOR-associated neurodevelopmental
disorders.
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Figure 1.1. PMSE patient brain exhibits lack of STRADA, cytomegaly, enhanced
mTORC1 activity, and neuronal heterotopia. A, Immunohistochemical analysis reveals a
lack of STRADA expression in PMSE versus control cortex. B, Luxol Fast Blue-Cresyl
Violet (LFB-CV) staining reveals numerous cytomegalic cells present in basal ganglia
(indicated by red arrows). C, Enhanced P-S6K1, P-S6, and c-Myc, in the absence of
enhanced P-RSK, in PMSE cortex indicates hyperactive mTORC1. D, PMSE cortex
exhibits heterotopic neurons present in the subcortical white matter, highly suggestive of
a neuronal migratory defect. Scale bars: A, 100 µm, 20 µm inset; B, 50 µm; C, 50 µm; D,
1 mm, 50 µm inset.

15

Figure 1.2. Knockdown of STRADA (STRADα) in vitro in mNPCs results in mTORC1dependent cytomegaly. A,C, GFP-tagged STRADA KD mNPCs have significantly
greater surface area than Scrambled shRNA transfected GFP-tagged control mNPCs.
B,D,E, This effect is fully prevented with 50 nM rapamycin treatment, indicating that
STRADA’s effects on cell size are mTORC1-dependent. The experiment was conducted
2 independent times; data are from n=30 cells per transfection and treatment condition.
*P < 0.01 versus other vehicle-treated control groups; #P < 0.01 versus vehicle-treated
STRADA KD cells. Scale bar, 20 µm.
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Figure 1.3. Knockdown of STRADA (STRADα) in vitro results in aberrant cortical
lamination. A,B, Transfection of neural progenitor cells in the ventricular/subventricular
zone (VZ/SVZ) via IUE with control GFP-tagged scrambled shRNA (Scram) at
embryonic day 14.0 (E14.0) results in a pattern of transfected cells migrating from the
VZ/SVZ through the intermediate zone (IZ) at E17.0. F,G, By E19.0, Scram transfected
cells have predominantly reached their destination of Layer II/III of the cortical plate
(CP). C,D, In contrast, transfection of neural progenitor cells with GFP-tagged STRADA
shRNA (STRADA KD) at E14.0 results in an abnormal retention of GFP+ cells in the
VZ/SVZ at E17.0, persisting at E19.0 (H,I). E,J, Statistical analysis indicates a failure of
STRADA KD neural progenitor cells to reach the CP at both E17.0 and E19.0, compared
with Scram control cells. n = 5 animals per condition at each time point. *P < 0.05 versus
CP Scram; **P < 0.05 versus VZ/SVZ Scram; #P < 0.05 versus CP STRADA KD. Scale
bars, 50 µm.
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Figure 1.4. STRADA (STRADα) knockdown in vivo through IUE results in depletion of
STRADA, enhanced mTORC1 activity, and a shift toward nuclear localization of LKB1.
A,B, Immunofluorescent staining reveals a significant decrease in STRADA expression
in cells transfected with GFP-tagged STRADA shRNA (STRADA KD) versus control
cells transfected with GFP-tagged scrambled shRNA (Scram). C,D, GFP+ STRADA KD
cells exhibit enhanced P-S6, indicative of aberrant mTORC1 activation. E,F, Knockdown
of STRADA results in a significant increase in the percentage of LKB1 localized to the
nucleus. Data are mean signal/background (B,D) or mean nuclear/total LKB1 (F). n = 10
cells per condition. *P < 0.05; **P < 0.01. Scale bars, 6.08 µm.
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Figure 1.5. Knockdown of STRADA (STRADα) in vitro in mNPCs results in increased
nuclear localization of LKB1. A,B, Wild-type and C,D, stably-transfected control
scrambled shRNA (Scram) mNPCs exhibit predominantly cytoplasmic LKB1. Nuclear
area is defined by Hoechst nuclear staining (in B,D,F). E,F,G, Stably-transfected
STRADA shRNA (STRADA KD) mNPCs exhibit a significant increase in the
percentage of total LKB1 localized in the nucleus. n = 132 wild-type cells, 143 Scram
cells, 149 STRADA KD cells. *P < 0.01 versus wild-type; #P < 0.01 versus Scram. Scale
bar, 20 µm.
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Figure 1.6. Replicating experimental in vitro and in vivo results, PMSE cortex exhibits
almost exclusively nuclear LKB1 localization, in contrast to cortex samples from several
other epileptic conditions. A, Approximately 95% of neurons in PMSE cortex exhbit
nuclear LKB1 staining. In contrast, in B, non-epileptic control cortex as well as cortex
from patients with C, cortical dysplasia focal epilepsy syndrome, D, sporadic type II focal
cortical dysplasia, E, hemimegalencephaly, and F, tuberous sclerosis complex; only
approximately 5% of neurons exhibit nuclear LKB1. Scale bars, 100 µm; 25 µm (insets).
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ENHANCED GROWTH FACTOR EXPRESSION IN TUBEROUS SCLEROSIS
COMPLEX2
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Abstract
Epidermal derived- (EGF), hepatocyte- (HGF), and vascular endothelial- (VEGF)
growth factors regulate angiogenesis and cell growth in the developing brain. EGF, HGF,
and VEGF modulate the activity of the mammalian target of rapamycin (mTOR) cascade,
a pathway regulating cell growth that is aberrantly activated in tuberous sclerosis complex
(TSC). We hypothesized that expression of EGF, HGF, VEGF and their receptors EGFR,
c-Met, and Flt-1, respectively, would be altered in TSC. We show by cDNA array and
immunohistochemical analysis that EGF, EGFR, HGF, c-Met, and VEGF, but not Flt-1,
mRNA and protein expression was upregulated in Tsc1 conditional knockout
(Tsc1GFAPCKO) mouse cortex. Importantly, these alterations closely predicted
overexpression of these proteins in TSC human cortex. Expression of EGF, EGFR, HGF,
c-Met and VEGF protein as well as HIF-1α, a transcription factor that regulates VEGF
levels and is also modulated by mTOR cascade activity, was enhanced in subependymal
giant cell astrocytomas (SEGAs; n=6) and tubers (n=10) from 15 TSC patients. Enhanced
expression of these growth factors and growth factor receptors in human SEGAs and
tubers and in the Tsc1GFAPCKO mouse provides potential target molecules for therapeutic
development in TSC.
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Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder resulting
from mutations in the TSC1 or TSC2 genes, which encode TSC1 and TSC2 proteins,
respectively (76, 77). Many individuals with TSC exhibit cognitive disability and autism
(78), and over 75% of TSC patients develop seizures (79-81). Examination of the brain
demonstrates cortical tubers and subependymal nodules (SENs) in over 70% of TSC
patients. Tubers are developmental malformations of the cerebral cortex highly associated
with epilepsy and neurocognitive abnormalities. SENs are nodular lesions (typically less
than 1 cm in size) located on the surfaces of the lateral and third ventricles. In
approximately 10-20% of TSC patients, subependymal giant cell astrocytomas (SEGAs)
arise within the lateral ventricles, often near the foramen of Monro. SEGAs are WHO
grade I tumors with low mitotic index as evidenced by Ki-67 immunoreactivity
suggestive of slow cellular proliferation (82, 83). It is widely believed that SENs grow to
form SEGAs, although the molecular mechanisms governing transformation from SEN to
SEGA are unknown (84). Both SENs and SEGAs consist of dysmorphic glial cells,
enlarged giant cells (GCs), and spindle shaped cells of unknown phenotype (85, 86).
Cellular immunoreactivity for GFAP, neurofilament, S-100, neuron specific enolase, and
synaptophysin proteins suggests that SEGAs contain both glial and neuronal cell types.
Lineage studies have demonstrated that SEGAs express cellular markers found in
progenitors derived from the subventricular zone (SVZ) adjacent to the lateral ventricles
(87, 88) and that many of these markers are also expressed in cortical tubers.
The TSC1 and TSC2 proteins combine to form a heterodimer that functions as a
direct upstream modulator of the mammalian target of rapamycin (mTOR) pathway,
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which integrates growth factor and energy level signals to promote several cellular
processes, including cell growth and proliferation (89) protein translation, and
angiogenesis. TSC1 and TSC2 mutations are associated with loss of inhibitory modulation
and consequent constitutive activation of the mTOR cascade, resulting in enhanced cell
size and proliferation, especially under conditions favoring cell growth. Previous studies
have suggested that altered growth factor expression may be associated with abnormal
cellular architecture in the brains of TSC patients. For example, differential expression of
neurotrophins and their receptors has been observed in cortical tubers (90), and TSC1TSC2 mediated control of mTOR is modulated by insulin-like growth factor-1 (IGF-1)
(91-93). Recent evidence also suggests that mTOR signaling is regulated by several
growth factors such as EGF and HGF and that TSC1-TSC2 may regulate downstream
expression of select angiogenic factors, such as VEGF via hypoxia inducible factor-1α
(HIF-1α) (94). For example, EGF regulates smooth muscle cell proliferation via its
receptor EGFR through mTOR signaling (95). VEGF expression is upregulated in the
Eker rat TSC model, in mouse embryonic fibroblasts lacking TSC2, and in facial
angiofibromas from TSC patients (94, 96, 97). Brain and kidney lesions in TSC exhibit
abnormally enhanced expression of the vascular endothelium protein marker CD31 (98).
Altered VEGF isoform D levels were observed in serum from TSC patients with
lymphangioleiomyomatosis (LAM) (99). Of note, enhanced VEGF expression in TSC
may occur via both mTOR-dependent and mTOR-independent mechanisms (100).
Altered expression of EGF, HGF, VEGF, and their receptors EGFR, c-Met, and
Flt-1 (VEGFR1) has not been investigated in the brain in TSC, yet considerable evidence
suggests that these factors play a pivotal role in the mTOR cascade’s influence on cellular
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phenotype, and could therefore provide insight into the mechanism of TSC cortical
pathogenesis. Thus, we assayed both mRNA and protein expression in the Tsc1
conditional knockout (Tsc1GFAPCKO) mouse and in human TSC brain tissue specimens as
a strategy to identify growth factors that could be targeted for therapeutic development in
TSC.
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Materials and Methods
Tsc1 Conditional Knockout Mice
Tsc1 conditional knockout (Tsc1GFAPCKO) mice were generated as previously
described (51) at The Washington University School of Medicine in accordance with the
guidelines established by The Animal Studies Committee of Washington University.
Samples at post-natal day 1 (P1) and P10 were analyzed for several reasons. First, at these
timepoints, the active phases of embryonic neuronal migration are completed and thus,
there is homeostatic expression of growth factors and receptors. Second, by P1 and P10
there is active expression of the Cre transgene in the brain and thus, adequate knockout of
Tsc1 could be documented. Third, we wanted to be certain that none of the altered growth
factor expression was a consequence of early seizures and altered behavioral phenotypes
that occur in these animals by P20.
Extraction of mRNA from Cerebral Cortex in the Tsc1GFAPCKO Mice
Poly(A) mRNA was extracted from the cerebral cortex of Tsc1GFAPCKO or wildtype (WT) mice (n=5 each) as described previously (90). The entire cortex from both
hemispheres was removed from the subcortical structures using a microscalpel at the level
of the mid-hippocampus. Poly(A) mRNA served as a template for in vitro cDNA
synthesis with avian myeloblastosis virus reverse transcriptase (AMVRT), and then
double stranded template cDNA was synthesized with T4 DNA polymerase I
(Boehringer-Mannheim) from extracted cDNA. mRNA was amplified from the double
stranded cDNA with T7 RNA polymerase (Epicentre Technologies) incorporating
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PCTP as a radiolabel. Amplified mRNA served as a template for a second round of
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cDNA synthesis with AMVRT, dNTPs, and N(6) random hexamers (BoehringerMannheim). cDNA generated from amplified mRNA was made double-stranded and
served as template for a second mRNA amplification, again incorporating
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PCTP

radiolabel. The radiolabeled, amplified mRNA was used as a probe for cDNA arrays.
cDNA Array Analysis
cDNA arrays containing full-length mouse EGF, EGFR, HGF, c-Met, VEGF, and
Flt-1 cDNAs were probed with
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PCTP radiolabeled mRNA amplified from the cortex

(one probe per array). All hybridization reactions were performed twice for each probe.
GAPDH cDNA was included to serve as positive hybridization control and pBlueScript
(pBS) plasmid cDNAs were used to define background levels of hybridization on each
array. Prehybridization (8 hours) and hybridization (24 hours) conditions were in 6X
SSPE buffer, 5X Denhardt's solution, 50% formamide, 0.1%SDS, and salmon sperm
DNA 200 mg/ml at 42oC. Blots were washed in 2X SSC. mRNA probe hybridization to
array cDNAs was determined by phosphorimaging and densitometry.
Human Tissue Specimens
Tuber and SEGA samples (n=15 patients; 7 females; 10 tubers, 6 SEGAs, mean
age 9.9 years; in one patient a tuber and SEGA were removed en bloc; see Table 2.1)
were obtained from patients with clinically diagnosed TSC. There were no significant
differences in age distribution in the TSC patient specimens used in the study. Tubers
were removed as part of surgery for the treatment of intractable epilepsy, and SEGAs
were removed to alleviate symptomatic hydrocephalus. Surgical tissue specimens were
obtained from Academic Medical Center, University of Amsterdam, The Netherlands,
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and Minnesota Epilepsy Group, St. Paul, MN. Surgical localization of the tuber resection
site reflected the seizure focus as determined by scalp or intracranial EEG monitoring.
SEGAs were identified pre-operatively by magnetic resonance imaging as progressively
enlarging lesions that exhibited enhancement with gadolinium. Three SENs were
obtained post-mortem from 3 TSC patients (Table 2.1) who died of non-neurological
causes. In these 3 specimens, morphologically normal cortex adjacent to histologically
defined tubers was also obtained. Clinical mutation testing (indicated as “Genotype” in
Table 1) results among the tuber, SEN, and SEGA patients revealed a TSC1 mutation in 5
patients and a TSC2 mutation in 10 patients; mutation data was unavailable from 3
patients (indicated as “NMI” in Table 2.1).
Post-mortem control brain tissue specimens (n=4; 2 females; Table 1) were
procured from the Brain and Tissue Bank for Developmental Disorders, University of
Maryland (http://medschool.umaryland.edu/BTBank/) from individuals who died of nonneurologic causes. Seizures were not terminal events in these patients and none had a
personal or family history of epilepsy or TSC. The cytoarchitecture of these specimens
was intact. Additional surgical epilepsy control tissue consisted of temporal neocortical
specimens (n=5; 3 females; Table 2.1) obtained from individuals undergoing temporal
lobectomy for intractable complex partial seizures (University of Pennsylvania Medical
Center). These patients had no history or clinical findings compatible with a diagnosis of
TSC and the histology of the tissue samples was intact (these specimens were classified
as epilepsy controls). All human tissue was obtained in accordance with protocols
approved by the University of Pennsylvania Institutional Review Board and Committee
on Human Research.
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Immunohistochemistry
All mouse and human tissue samples were immersion-fixed in 4%
paraformaldehyde, embedded in paraffin, and sectioned at 8mm. All fixed tissue blocks
were hydrated through graded ethanols. Slides were pretreated with antigen unmasking
solution (Vector Labs, Burlingame, CA) prior to immunostaining reactions. Sections were
probed one of the following antibodies: EGF (1:1000 dilution, rabbit polyclonal, Santa
Cruz, Burlingame, CA), EGFR (1:100, rat polyclonal, Santa Cruz), EGFRvIII variant
(courtesy D. O’Rourke M.D., Department of Neurosurgery, University of Pennsylvania,
Philadelphia, PA), phospho-EGFR (p-EGFR, phospho Y1068, 1:250, rabbit monoclonal,
Abcam, Cambridge, MA), HGF (1:500, mouse monoclonal, Abcam), c-Met (1:10
dilution, rabbit polyclonal, Abcam), VEGF (1:50, mouse monoclonal, Abcam), Flt-1
(1:100, mouse monoclonal, Santa Cruz), HIF-1a (1:1500, mouse monoclonal, Abcam),
phospho-S6 ribosomal protein (p-S6, Ser235/236; 1:100, rabbit polyclonal, Cell
Signaling, New England Biolabs, Beverly, MA), or S6 ribosomal protein (detects
endogenous S6 expression including both phosphorylated and non-phosphorylated
isoforms, 1:100, rabbit monoclonal, Cell Signaling) overnight at 4oC, and with secondary
antibodies at room temperature for 1 hour. The slides were visualized using avidin-biotin
conjugation (Vectastain ABC Elite; Vector Labs) with 3,3'-diaminobenzidine. Following
immunolabeling, sections were dehydrated through graded ethanols and xylene and
coverslip-mounted (Permount).
Quantitative Cell Counts
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Three representative contiguous digital photos were obtained (20X magnification)
from each mouse brain tissue section using image acquisition and analysis software (Spot
RT CCD camera, Diagnostic Instruments, Inc. and Phase 3 Imaging System integrated
with Image Pro Plus; Media Cybernetics, Silver Spring, MD). The three images spanned a
1 mm2 region of interest (ROI) within the lateral neocortex that was operationally defined
and standardized across all cortex specimens as dorsolateral cerebral cortex at the level of
the rostral hippocampus mid-way between the superior sagittal sulcus and the rhinal
sulcus (Bregma coordinate -1.70mm). The area of the cortex for each ROI was
determined with a glass micrometer under light microscopy.
In the human specimens, we were particularly interested in the number of GCs
that expressed each protein growth factor marker. Thus, GCs were defined using maximal
cell diameter based on cresyl violet and hematoxylin and eosin staining for quantitative
cell counting analysis. Representative digital photos were obtained (20X magnification)
under light microscopy from each tissue section (n=3 sections per case) using image
acquisition and analysis software as above. Each image spanned a 1 cm2 region of interest
(ROI). Prior to final assignment as a GC by the software, each ROI was visually
inspected and cellular elements erroneously included in the computerized analysis were
deleted. Mean maximal diameter (cell diameter at its largest aspect) was calculated using
Image Pro Plus software as expressed in pixel units that were converted to microns by
direct calibration with a micrometer.
The relative optical density ratio (ODR) of labeled cells was calculated using
Image Pro Plus software using a previously defined approach (90). The ODR is calculated
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by determining the level of pixel staining density in labeled cells versus the pixel density
of the non-cellular background (the cell densities are digitally subtracted from the image).
An ODR >3 was used as a threshold to define immunopositivity for a given antibody. In
the mouse, the total numbers of p-S6 immunolabeled cells were determined for each case
and then expressed as a mean (+SEM) for Tsc1GFAPCKO and control specimens. For
growth factors, we used a semi-quantitative scale (0, no staining to ++++, intense labeling
across most cells in each ROI) to represent labeling density in each ROI. The size of p-S6
immunolabeled cells was defined using maximum cell diameter and determining the
mean (+SEM). In the human specimens, the total numbers of morphologically identified
GCs were determined in each ROI for each case and the mean (+SEM) numbers of GCs
in ROIs were determined across all 10 tubers and 6 SEGAs. Statistically significant
differences in GCs expressing individual protein markers were determined by Student’s ttest (p<0.05).
Western Analysis
Lysates of wildtype and Tsc1GFAPCKO cortex were analyzed for p-S6 protein levels. A
DuPont Kinetic Microplate Reader was used to approximate 15 µg total protein for each
of the samples, which were individually loaded into separate wells of a 4-15% Tris-HCl
polyacrylamide gel (Bio-Rad Laboratories), and electrophoresed at 60V. Proteins were
then transferred overnight at 4oC onto a polyvinylidene difluoride (PVDF, Millipore)
membrane. Membranes were incubated in a 5% non-fat dry milk (NFDM) blocking
solution for 1 hour at room temperature (RT) and then probed with rabbit anti-p-S6
ribosomal protein (Ser235/236; 1:1000, overnight at 4oC, Cell Signaling) antibodies.
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Rabbit anti-GAPDH (1:1000, 1 hour at RT, Cell Signaling) and rabbit anti-β-actin
(1:1000, 1 hour at RT, Cell Signaling) served as protein loading controls. Membranes
were then incubated for 1 hour at RT with horseradish peroxidase (HRP)-conjugated
donkey anti-rabbit IgG (1:3000, GE Healthcare). Membranes were washed and developed
using either ECL or ECL Plus Western Blotting Detection Reagents (Amersham, GE
Healthcare), as needed for HRP visualization.

Statistical Analysis
The expression of each mRNA was determined by analysis of the radiolabeled
mRNA-cDNA hybridization intensity on each array using ImageQuant5.0 software. Nonspecific hybridization to pBS plasmid cDNA was subtracted from the hybridization
intensity of each mRNA-cDNA to define specific hybridization intensity. The relative
hybridization

intensity

for

each

mRNA

was

determined

by

averaging

the

phosphorimaging density of all the mRNA-cDNA hybrids on each individual array and
then expressing each mRNA-cDNA hybrid as a percentage of the average hybridization
intensity of the entire array. Differences in relative mRNA abundance were determined
using a one-way ANOVA and a Bonferroni post-hoc correction was applied to each
univariate ANOVA. If a significant difference was found with a Bonferroni-adjusted
ANOVA, individual post-hoc comparisons were made using the Fischer’s test (p<0.05
was considered significant).
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Results
Enhanced S6 Phosphorylation in the Tsc1GFAPCKO Mouse Cortex and Human TSC Brain
Tissue
The expression level of Tsc1 mRNA was determined at P1 and P10 in the cerebral
cortex in Tsc1GFAPCKO mice. At P1, Tsc1 mRNA levels were reduced by 86+4% and at
P10, levels were reduced by 92+7% compared to wild-type (Wt) mice (n=10 sections
each in Tsc1GFAPCKO and Wt control samples at each timepoint, p<0.05; Figure 2.1C).
Expression of Tsc2 mRNA at P1 and P10 in cortex from the Tsc1GFAPCKO mice did not
differ from that observed in Wt mice.
There was a low level of baseline p-S6 protein expression in cortical neurons and
astrocytes of control Wt mice at P1 and P10. P-S6 labeled astrocytes were observed
throughout all cortical layers. In neurons, p-S6 expression was observed primarily within
the somatic and dendritic cytoplasm of pyramidal cells in layers III and V. At both P1 and
P10, there was a clear increase in the number of p-S6 labeled cortical cells in the
Tsc1GFAPCKO mouse brain compared with control Wt brains (Figure 2.1A). Quantitative
cell counts of p-S6 labeled cells were performed at P1 and P10, which antedates the onset
of clinical seizures in these mice. There was a significant increase in the number of p-S6
labeled cells at P1 (115 control, and 336 Tsc1GFAPCKO mouse, p<0.05) and P10 (665
control, and 1319 Tsc1GFAPCKO mouse, p<0.05) (Figure 2.1B). Western assay revealed
markedly enhanced S6 protein phosphorylation in Tsc1GFAPCKO mice, compared to Wt
control (Figure 2.1C) (55). Immunolabeling of human TSC cortex also revealed an
increase in phosphorylation of S6, relative to control cortex, with no corresponding
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increase in endogenous S6 (both phosphorylated and non-phosphorylated isoforms)
expression overall (Supplemental Figure). Increased S6 phosphorylation in tubers is
consistent with previous findings in TSC and confirms mTOR hyperactivity in these
lesions (40).
Increased Growth Factor mRNA Expression in Tsc1GFAPCKO Mice
The expression of EGF, EGFR, HGF, c-Met, and VEGF mRNAs in cerebral
cortex was increased at P1 and P10 in Tsc1GFAPCKO mice compared with Wt mice (Fig.
2). EGFR mRNA levels were increased 9.3-fold and 7.1-fold at P1 and P10, respectively,
while EGF was increased 2.1-fold and 2.8-fold, HGF was increased 3.3-fold and 4-fold,
c-Met was increased 3-fold at both timepoints, and VEGF was increased 5.8-fold and 5.9fold at P1 and P10, respectively. However, Flt-1 mRNA expression in Tsc1GFAPCKO
mice did not differ from that of Wt mice at either timepoint (not shown). Of note, GFAP
mRNA expression in the cortex was increased by 3.8-fold at P1 and 6.4-fold at P10,
consistent with previous reports that there is progressive increase in the number of
astrocytes in the Tsc1GFAPCKO mice (51).
Increased Growth Factor Protein Expression in Tsc1GFAPCKO Mice
Low levels of EGF, EGFR, HIF-1a, c-Met, and Flt-1 expression were observed in
Wt mice at P1 and P10, whereas VEGF and HGF protein expression levels were higher at
both timepoints. Since a dramatic alteration of laminar architecture is not a feature of the
Tsc1GFAPCKO mouse cortex, we did not observe substantive changes in laminar
expression of any of the growth factors or their receptors. Rather, our findings suggested
enhanced expression in the expected distribution of each identified layer. For example, in
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the Wt mice, EGF was expressed at low levels across the cortical plate at both P1 and P10
whereas in the Tsc1GFAPCKO mouse, there was a global increase in EGF expression
across all layers. HGF, c-Met, and VEGF exhibited an alteration in laminar expression
profiles (see Table 2.2) with enhanced expression in deeper cortical layers in the
Tsc1GFAPCKO mouse. The expression of EGF, EGFR, HGF, c-Met, VEGF, and HIF-1a
proteins was increased at P1 and P10 in Tsc1GFAPCKO mice compared with Wt mice
(Figures 2.3-2.5) in a profile that was similar, though not identical to mRNA expression.
However, similar to its corresponding mRNA, Flt-1 expression in Tsc1GFAPCKO mice did
not differ from that of Wt mice at either timepoint (not shown). By P10, immunoreactive
cells were identified in cerebral cortex across all 6 layers, and both neurons and astrocytes
exhibited immunolabeling.
Increased Growth Factor Protein in Human TSC Brain Tissue
The mean maximal cell soma diameter of the GCs was 112.4 µm (range 104-125
µm) and thus, this parameter was used to generate cell counts for each individual protein
marker. The expression profile for each protein marker was heterogeneous across the
tubers and SEGAs. In some specimens, even when corrected for differing numbers of
GCs across each case, there was robust expression of individual proteins, while in other
specimens fewer numbers of cells were labeled (Table 2.3). For some proteins detailed
below, there was enriched expression in GCs in deeper portions of the tuber (i.e., within
the subcortical white matter) (Table 2.3, WM), whereas for others, protein expression
was observed in GCs throughout the thickness of the lesion (Table 2.3, ALL).
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Immunohistochemical analysis demonstrated that EGF, EGFR, HGF, c-Met,
VEGF, and HIF-1α protein expression was markedly increased in tuber (Figures 2.6-2.9)
and SEGA (Figure 2.10) specimens when compared with specimens of age-matched,
post-mortem, and non-TSC epilepsy cortex. Cellular expression of growth factor proteins
was observed in GCs throughout the thickness of each tuber specimen, from pial surface
to subcortical white matter. For example, expression of EGF and EGFR was primarily
observed in GCs in tubers (Figure 2.6) and SEGAs (Figure 2.10). Expression of the
phospho-isoform of EGFR was also enhanced in tubers compared with control cortex.
The EGFRvIII variant protein isoform is frequently identified as an overexpressed protein
in certain types of astrocytomas and is linked to enhanced EGF signaling in these tumors.
However, in contrast to native EGFR, there was no expression of EGFRvIII variant
protein isoform in tubers or SEGAs (data not shown). HGF and c-Met expression was
most marked in GCs and some of the surrounding dysmorphic neurons, within tubers
(Figure 2.7) and SEGAs (Figure 2.10). VEGF was robustly expressed by GCs and
capillary endothelial cells in tubers (Figure 2.8). Additionally, the level of VEGF
expression in non-tuber cortex from TSC patients was increased relative to the level of
VEGF expression in cortex from non-TSC epilepsy control patients (Figure 2.9). The
distribution of HIF-1α expression was similar to that of VEGF, although HIF-1α
expression was not as widespread in tubers and was often seen in small clusters of cells,
especially in the subcortical white matter (Figure 2.8). In contrast, the levels of the
VEGF receptor Flt-1 were not increased in either tubers or SEGAs (not shown).
Growth factor and growth factor receptor expression in non-tuber TSC cortex did
not differ from non-TSC epilepsy control cortex, with the exception of VEGF.
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Specifically, rare GCs at the edge of the resection margin exhibited VEGF expression and
appeared as a stark contrast to the surrounding tissue, and there were scattered VEGF
immunolabeled cells in the non-tuber TSC cortex that were more frequent in number than
in control non-TSC epilepsy cortex. These findings argued against a non-specific effect of
anti-seizure medications, recurrent seizures, age, or post-mortem interval on protein
expression.
Additionally, an important finding was that growth factor and growth factor
receptor expression was not enhanced in SENs, and appeared within these nodules to be
similar to expression levels in control tissue (data not shown). These findings suggest that
enhanced growth factor expression was indeed specific for tubers and SEGAs and hint
toward a possible role of growth factors in the SEN to SEGA transformation.
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Discussion
This is the first study to demonstrate enhanced EGF, EGFR, HGF, c-Met, and
VEGF expression in association with loss of Tsc1 in the mouse and with human TSC
brain pathology. We were specifically interested in growth and angiogenic factors
because of the documented enhancement of cell proliferation and angiogenesis in TSCassociated lesions such as angiomyolipomas and SEGAs. The expression of EGF, EGFR,
HGF, c-Met, and VEGF mRNAs was increased at P1 and P10 in Tsc1GFAPCKO mouse
cortex, and these findings predicted similar changes in human TSC tubers and SEGAs.
Increased mTOR signaling was demonstrated in Tsc1GFAPCKO mouse brain and human
TSC cortical tubers and SEGAs, as evidenced by increased phosphorylation of S6 protein.
We conclude that enhanced expression of EGF, EGFR, HGF, c-Met, and VEGF is linked
at least in part to altered TSC1 or TSC2 function and aberrant mTOR signaling.
The Tsc1GFAPCKO mouse has been well-characterized, and recent studies
demonstrate that mTOR antagonism with rapamycin can ameliorate seizures and prevent
premature death in this strain (55). Our study is the first to define the temporal pattern of
mTOR activation, as evidenced by phosphorylation of S6 protein in the cortex of these
animals. There is clearly a time-dependent increase in S6 phosphorylation consistent with
the ongoing effects of loss of Tsc1 following conditional inactivation. Indeed, a greater
number of p-S6 immunolabeled cells were identified at P10 than P1. We submit that
changes in growth factor expression in the Tsc1GFAPCKO mice did not reflect either
seizures or behavioral alterations that appear later in this strain (approximately P20-P30)
and rather represent direct effects of loss of Tsc1.
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In contrast, the effects of loss of TSC1 or TSC2 on expression of EGF, EGFR,
HGF, c-Met, VEGF, and HIF-1α in neural cells have not yet been studied, and we are the
first to report changes in these growth factors and their receptors in TSC brain tissue with
defined genotypes. Our findings suggest that altered growth factor expression may be a
consequence of loss of either TSC1 or TSC2. EGFR plays a pivotal role in regulating
astrocyte proliferation during development and has been implicated in aberrant cell
growth control in malignant gliomas. EGFR has been localized to radial glial cells in the
embryonic ventricular zone and is a marker for those that differentiate into astrocytes.
Both HGF and its tyrosine kinase receptor c-Met are expressed by stem cells in the
subventricular zone (101), and in view of the prior demonstration of stem cell markers
such as nestin in tubers (102), these growth factors could also serve to characterize tubers
as phenotypically immature. Like EGFR, HGF and c-Met are expressed in human
gliomas and are believed to function in cell proliferation and angiogenesis (for review see
Abounader and Laterra (101)). Functional blockade of EGFR and c-Met inhibits tumor
growth. Prior studies have suggested that enhanced HGF expression in proliferating
hepatocytes is mTOR-dependent (103). Changes in EGF, EGFR, HGF, and c-Met
expression were identified in the setting of diminished TSC1 or TSC2 function, i.e. the
Tsc1GFAPCKO mouse or human tuber or SEGA specimens, but not in surrounding nontuber cortex and not within SENs, suggesting that complete TSC1 or TSC2 inactivation
and commensurate hyperactivation of the mTOR pathway may be necessary to induce
these effects.
VEGF expression is directly modulated by TSC1 and TSC2 via both mTORdependent and mTOR-independent pathways in vitro (100). Thus, among the growth
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factor genes assayed, alterations in VEGF mRNA and protein levels may be most
sensitive to loss of TSC1 or TSC2 (97). High levels of VEGF mRNA expression have
been reported in angiomyolipomas and in serum from human TSC patients (98, 104).
VEGF expression was enhanced following Tsc1 knockout in vivo in mice, and we
observed enhanced VEGF expression in human tubers and SEGAs as well as in perituberal cortex.
Increased mTOR signaling, corresponding to loss of TSC1/TSC2 inhibition, has
been demonstrated specifically in SEGAs (41) and tubers (40). Thus, the findings in
human TSC tissue specimens of increased expression of EGF, HGF, VEGF, and their
receptors primarily within these focal areas of mTOR cascade dysregulation suggests that
reduction of TSC1 or TSC2 could lead to increased EGF, HGF, or VEGF levels via
mTOR. Indeed, our results support previous observations in mouse kidney cells and
fibroblasts demonstrating enhanced VEGF detected in either Tsc2 heterozygous (+/-) or
null (-/-) cells (97).
These results provide a link between aberrant mTOR cascade activation and
enhancement of three new candidate growth factors that could be targeted for future
therapeutic trials in TSC. EGFR, HGF, and VEGF can be blocked with specific
antagonists, perhaps in association with rapamycin, as a strategy to reduce the size of
tubers or SEGAs in TSC and diminish the potential toxicity of any one therapeutic
compound.
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Table 2.1. TSC and Control Patient Demographics

Sample
Tuber
Tuber
Tuber
Tuber
Tuber
Tuber
Tuber
Tuber
Tuber
Tuber*
SEGA*
SEGA
SEGA
SEGA
SEGA
SEGA
SEN
SEN
SEN
Epilepsy
Control
Epilepsy
Control
Epilepsy
Control
Epilepsy
Control
Epilepsy
Control
Control
Control
Control
Control

Age

Location

Genotype

4 years
9 years
3 years
9 years
3 years
2 years
4 years
6 years
7 years
10 years
10 years
14 years
21 years
22 years
19 years
16 years
27 years
37 years
41 years
6 years

Frontal
Frontal
Temporal
Frontal
Temporal
Temporal
Frontal
Temporal
Frontal
Frontal
Lat Vent
Lat Vent
Lat Vent
Lat Vent
Lat Vent
Lat Vent
Lat Vent
Lat Vent
Lat Vent
Temporal

TSC1
TSC2
TSC2
TSC2
TSC1
TSC1
NMI
TSC2
NMI
TSC2
TSC2
TSC1
TSC2
TSC1
TSC2
NMI
TSC2
TSC2
TSC2
NMI

14 years

Temporal

NMI

12 years

Temporal

NMI

9 years

Temporal

NMI

16 years

Temporal

NMI

4 years
9 years
11 years
11 years

Frontal
Frontal
Temporal
Frontal

NMI
NMI
NMI
NMI

	
  

Table depicts age at time of surgery, lobar location of resection and TSC genotype. Lat
Vent, lateral ventricle; NMI, no mutation identified; * specimen contained both SEGA
and cortical tuber.
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Table 2.2. Laminar Expression of Growth Factors in Wild-type Versus
Tsc1GFAPCKO Mice at P10

Protein

WT

Score

Tsc1GFAPCKO

Score

EGF

ALL

+

ALL

+++

EGFR

II-IV

+

II-IV

++++

HGF

I-III

++

ALL

++++

HIF-1a

ALL

0

ALL

++

c-Met

II-III

+

ALL

+++

VEGF

II-III

++

II-V

++++

Semi-quantitative scale (0, no staining; +, very few labeled cells; ++, >20 labeled cells;
+++, > 50 labeled cells; ++++, intense labeling across most cells in each ROI) to represent
labeling density in each ROI. Roman numerical convention indicates expression of each
growth factor within specified cortical layers; ALL, expression in all cortical layers.
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Table 2.3. Growth Factor and Growth Factor Receptor Expression in Tubers

Protein

WT

Score

Tsc1GFAPCKO

Score

EGF

ALL

+

ALL

+++

EGFR

II-IV

+

II-IV

++++

HGF

I-III

++

ALL

++++

HIF-1a

ALL

0

ALL

++

c-Met

II-III

+

ALL

+++

VEGF

II-III

++

II-V

++++

Table depicts percent of morphologically identified GCs expressing each protein marker,
across all 10 tuber specimens. WM reflects relative enrichment of labeled cells in
subcortical white matter; ALL reflects expression detected across all layers.
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Figure 2.1. Enhanced S6 phosphorylation (p-S6) in Tsc1GFAPCKO mouse cortex. (A), At
P1 and P10 timepoints, Tsc1GFAPCKO cortex (Tsc1 KO) shows increased p-S6
expression compared to wild-type (Wt) cortex. Photo taken at the level of the peri-rhinal
sulcus; inset, magnification 40X. Scale bars, 20 µm. (B), Graph showing quantitative
cell counts of p-S6 labeled cells in wild-type (Wt) and Tsc1GFAPCKO (CKO) mice at
P10. Note increased numbers of p-S6 labeled cells in CKO. (C), Western blot depicting
increased p-S6 levels in Tsc1GFAPCKO versus Wt mouse cortex homogenates, and cDNA
array hybridization depicting reduced Tsc1 mRNA expression in CKO versus Wt mice.
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Figure 2.2. Increased expression of EGF, EGFR, HGF, c-Met, and VEGF mRNAs in
Tsc1GFAPCKO versus Wt mouse cortex at P1 (red) and P10 (blue). Bars represent mean
change in relative abundance expressed as fold change relative to Wt cortex (lines above
bars depict SEM; all significant p<0.05). Increased expression of GFAP mRNA at each
timepoint is depicted in black.
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Figure 2.3. Enhanced expression of EGF and EGFR proteins in Tsc1GFAPCKO (Tsc1
KO) mouse versus wild-type (WT) mouse cortex at P1 and P10 timepoints; inset,
magnification 40X. Scale bars, 20 µm. Note EGF expression in heterotopic cells in white
matter at P10.
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Figure 2.4. Enhanced expression of HGF and its receptor c-Met in Tsc1GFAPCKO (Tsc1
KO) mouse versus wild-type (WT) mouse cortex at P1 and P10; inset, magnification
40X. Scale bars, 20 µm. Note expression of HGF in ectopic cell clusters depicted at P1
and throughout cortex at P10. In contrast, c-Met expression is more widespread across
the cortex at both time points.
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Figure 2.5. Enhanced expression of VEGF and HIF-1α proteins in Tsc1GFAPCKO (Tsc1
KO) mouse versus wild-type (WT) mouse cortex at P1 and P10; inset, magnification
40X; depicts VEGF or HIF-1a labeling in individual cells or small clusters of cells. Scale
bars, 20 µm.
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Figure 2.6. Increased EGF and EGFR (both phosphorylated and non-phosphorylated
isoforms) expression in human TSC (tuber) versus control cortex; inset, magnification
40X. Scale bars, 20 µm.
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Figure 2.7. Increased HGF and c-Met expression in human TSC (tuber) versus control
cortex; inset, magnification 40X. Scale bars, 20 µm.
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Figure 2.8. Increased VEGF and HIF-1α expression in human TSC (tuber) versus
control cortex. Note VEGF expression in dysmorphic GCs as well as in capillary
endothelium; inset, magnification 40X. Scale bars, 20 µm.
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Figure 2.9. Increased expression of VEGF in a tuber specimen from a TSC patient,
compared with non-tuber cortex in the same TSC patient and with non-TSC epilepsy
control cortex (top row, 10X magnification; bottom row, 20X). In tuber cortex, there is
robust cellular VEGF expression. In non-tuber cortex from the same TSC patient, there
is overall less cellular VEGF expression than in tubers but more than in non-TSC
epilepsy control cortex, in which there is little cellular VEGF expression. Scale bars, 100
µm.
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Figure 2.10. Expression of EGF (A), EGFR (B), HGF (C), and VEGF (D) in SEGAs.
Scale bar, 100 µm.
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CHAPTER 3

LOSS OF STRADA IN PRETZEL SYNDROME DISRUPTS NEURONAL
PATHFINDING THROUGH ENHANCED IRS1 SIGNALING3

_______________________________________________________________________
3
Much of this work was originally published in Science Translational Medicine, Vol. 5,
No. 182, April 2013. Parker, W.E., Orlova, K.A., Parker, W.H., Birnbaum, J.F.,
Krymskaya, V.P., Goncharov, D.A., Baybis, M., Helfferich, J., Okochi, K., Strauss,
K.A., and Crino, P.B. Rapamycin Prevents Seizures After Depletion of STRADA in a
Rare Neurodevelopmental Disorder. Published by AAAS.
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Abstract
Heterotopic neurons in the subcortical white matter are a histopathological
finding in many neurodevelopmental disorders associated with intractable epilepsy.
Polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE,
colloquially named “Pretzel Syndrome”) is a neurodevelopmental disorder resulting from
a loss-of-function mutation in STE20-related kinase adaptor alpha (STRADA), which
encodes the pseudokinase STRADA. Postmortem PMSE brain tissue exhibits numerous
heterotopic neurons, and STRADA knockdown (KD) in a mouse model results in
heterotopic neurons in the subventricular zone, suggesting that STRADA may affect
neuronal migration and pathfinding, although the role STRADA plays in this process has
not yet been identified. We demonstrate that depletion of STRADA in vitro in mouse
neural progenitor cells (mNPCs) results in aberrant pathfinding and disrupted polarity,
associated with reduced actin polymerization. We define the mechanism for this effect as
constitutive mTORC1- and p70S6K-dependent phospho-inhibition of IRS1 resulting in
disinhibition of cofilin and actin depolymerization. Treatment of STRADA-deplete
mNPCs with the mTORC1 inhibitor rapamycin or p70S6K inhibitor PF-4708671 rescues
the pathfinding and polarity defects. We confirm the link between enhanced mTORC1
activity and cofilin signaling by demonstrating aberrant IRS1 phosphorylation in PMSE
patient cortex. STRADA-deplete human fibroblasts extracted from PMSE patients
exhibit disrupted migration associated with IRS1 phospho-inhibition and depolymerized
actin. Finally, we demonstrate that inhibition of mTORC1 with rapamycin rescues the
neural migratory defect associated with STRADA KD in the developing mouse brain.
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We define STRADA as a pivotal regulator of neural pathfinding, migration, and polarity
via mTORC1 and IRS1 signaling to cofilin and regulation of actin assembly.
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Introduction
Heterotopic neurons within the subcortical white matter are a common
histopathological finding identified in brain specimens resected from patients with
intractable epilepsy (105), tuberous sclerosis complex (TSC), an autosomal dominant
disorder highly associated with severe epilepsy (106), and all subtypes of focal cortical
dysplasia associated with intractable pediatric epilepsy (107). Heterotopic neurons
contribute to pathogenesis of epilepsy by establishing aberrant network connectivity
(108). It has been proposed that heterotopic neurons result from impaired pathfinding or
migration into the nascent cortical plate during corticogenesis, although the molecular
mechanisms responsible for impaired movement have not been fully defined.
Loss-of-function mutation of LYK5/STRADA is associated with “Pretzel
Syndrome” (polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome,
PMSE; OMIM #611087), a recessive neurodevelopmental disorder characterized by
intractable epilepsy and severe cognitive impairment, identified in the Old Order
Mennonite population (61). Numerous heterotopic neurons are observed in PMSE,
suggesting a neural migratory defect and priming consideration of STRADA as a pivotal
regulator of neuronal pathfinding and migration (12, 61). All PMSE patients share a
common homozygous truncating deletion of exons 9-13 of STRADA, removing the
protein interacting domains for complex formation with the kinase LKB1, a known
regulator of mammalian target of rapamycin (mTOR) (6). It is estimated that
approximately 4% of the more than 40,000 Old Order Mennonite individuals in Ohio,
Pennsylvania, and New York may be hemizygous for STRADA deletion.
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The STRADA/LKB1 protein complex inhibits mTORC1 signaling via phosphoactivation of AMP-activated kinase (AMPK) and tuberous sclerosis 2 (TSC2) in gut,
skin, and brain (12, 14, 16, 23). STRADA knockdown in vitro leads to enhanced
mTORC1 signaling in lymphoblasts and neural progenitor cells, and in vivo, results in
clusters of heterotopic neurons within the murine post-natal subventricular zone (12).
Knockdown of stk25, a potential STRADA interacting protein, leads to altered Golgi
assembly and polarity of mature neurons, an effect antagonized by reelin (109), and in
non-neural cancer cell lines, STRADA modulates cell polarity via signaling to PAK1
(110). While LKB1 has been implicated in neuronal polarization, axon specification, and
dendrite growth (10, 65), a direct assessment of a role for STRADA in migration and
pathfinding of embryonic neurons or neural progenitor cells or of the cell signaling
mechanisms responsible for linking STRADA to progenitor cell migration, has not been
reported.
We show that STRADA is a pivotal regulatory protein that governs pathfinding in
neural progenitor cells via an mTORC1-p70S6K-dependent mechanism, activating IRS1,
inhibiting cofilin, and polymerizing actin, and that PAK1 and LIMK are key signaling
links between STRADA, IRS1, and cofilin. mTORC1 inhibition rescues aberrant
neuronal migration and pathfinding in vitro and in vivo in a mouse model of PMSE. Our
data suggest that PMSE provides a novel disease model to study mechanisms leading to
neuronal heterotopia.

59

Materials and Methods
mNPC culture and transfection
Stable transfection of puromycin-resistant shRNA plasmids in mNPCs (provided by J.
Wolfe, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA) (111) was
established using either puro-shRNA STRADA to create a stable STRADA KD line or
puro-shRNA scram to create a control line (KM41633P; SABiosciences), as previously
described (12). Cells were cultured on poly-D-lysine-coated plates (10 µg/ml; SigmaAldrich) in complete media consisting of DMEM/F12 (Invitrogen) supplemented with
1% N2 (Invitrogen), 1% FBS (Sigma-Aldrich), 1% penicillin/streptomycin (Invitrogen),
20 ng/ml basic fibroblast growth factor (Promega), and 5 µg/ml heparin (Sigma-Aldrich).
To maintain stable transfection, selective pressure was applied with 6 µg/ml puromycin
(Invitrogen).

Mouse embryonic fibroblasts (MEFs)
Lkb1+/+ and Lkb1-/- MEFs were a gift from the laboratories of L. Cantley (Beth Israel
Deaconess Medical Center, Boston, Massachusetts, USA) and R. Shaw (Salk Institute for
Biological Sciences, La Jolla, California, USA) (19, 23). Cells were cultured in DMEM
(Invitrogen)

supplemented

with

10%

FBS

(Sigma-Aldrich)

and

1%

penicillin/streptomycin (Invitrogen). For protein quantification assays, MEFs were serum
starved overnight to attenuate basal mTORC1 activity and pre-treated with AICAR (2
mM; Cell Signaling) to stimulate AMPK for 2 hours prior to lysis (12).
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Human fibroblast extraction and culture
PMSE patient (3), parent (2), and normal control (1) fibroblasts were obtained from skinpunch biopsies at the Clinic for Special Children in Lancaster, Pennsylvania, USA,
following informed consent. Fibroblasts were extracted from tissue samples by
incubation in 0.25% Trypsin/EDTA (Gibco) overnight at 4oC. The next day, epidermis
was removed, and dermis was digested with Collagenase P (Roche) buffered in 130 mM
sodium chloride (Sigma-Aldrich), 10 mM calcium acetate (Sigma-Aldrich), and 20 mM
HEPES buffer (Gibco) for 30 minutes at 37oC. Then 0.5% Trypsin/EDTA (Gibco) was
added, and the mixture was incubated at 37oC for an additional 10 minutes before
neutralization with fibroblast culturing media, composed of DMEM (Gibco)
supplemented with 10% FBS (Sigma-Aldrich), 10 mM HEPES buffer (Gibco), 1%
penicillin/streptomycin (10,000 u/ml penicillin, 10 mg/ml streptomycin stock; Gibco),
and 1% fungizone (250 µg/ml stock; Gibco). Fibroblasts were pelleted through
centrifugation for 5 minutes at 1500 rpm, and the pellet was resuspended in fibroblast
culturing media to obtain the desired cells. For protein quantification assays, fibroblast
media was supplemented with CAMKK inhibitor STO-609 (5 µM; Tocris) and AMPK
activator AICAR (2 mM; Cell Signaling) at 6 hours and 4 hours, respectively, prior to
cell lysis, to enable isolation of STRADA-dependent inhibition of mTORC1 signaling.
Rapamycin (100 nM; Cell Signaling) or p70S6Ki (PF-4708671, 10 µM; Pfizer
Pharmaceuticals) was applied for 2 hours prior to cell lysis.
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Western blotting
Cells were lysed and lysates electrophoresed according to previously-established protocol
(12). The following primary antibodies were used: rabbit polyclonal to LYK5 (1:500;
Abcam), rabbit monoclonal to phospho-S6 ribosomal protein (Ser235/236, 1:1000; Cell
Signaling), rabbit monoclonal to phospho-4EBP1 (Thr37/46, 1:1000; Cell Signaling),
rabbit polyclonal to IRS1 (phospho S636 + S639, 1:500; Abcam), rabbit polyclonal to
phospho-PAK1 (Ser144)/PAK2 (Ser141) (1:1000; Cell Signaling), rabbit polyclonal to
phospho-LIMK1 (Thr508)/LIMK2 (Thr505) (1:1000; Cell Signaling), rabbit monoclonal
to phospho-cofilin (Ser3, 1:1000; Cell Signaling), and rabbit monoclonal to GAPDH
(1:1000; Cell Signaling).

Immunocytochemistry
Scram and STRADA KD mNPCs plated on coverslips and subjected to the described
migration assay were fixed in 4% PFA at room temperature for 20 minutes,
permeabilized with 0.3% Triton X-100 (Sigma) in PBS (Gibco), and blocked for 2 hours
in 5% normal goat serum (Vector Laboratories). Cells were incubated in mouse antiGM130 monoclonal Ab (1:100; BD Transduction Laboratories) overnight at 4oC. AlexaFluor 488 goat anti-mouse secondary Ab (Invitrogen) was applied for 1 hour at room
temperature. Cells were then blocked in 1% bovine serum albumin (BSA; SigmaAldrich) for 30 minutes. Phalloidin (1:40; Invitrogen) was applied for 20 minutes,
followed by Hoechst nuclear stain (0.0001 µg/µl; Invitrogen). Cells were visualized and
images captured using fluorescence microscopy, as specified above. Golgi-specific
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labeling was confirmed by co-staining a subset of coverslips with rabbit anti-Giantin
polyclonal Ab (1:500; Abcam) and Alexa-Fluor 594 goat anti-rabbit secondary Ab
(Invitrogen).

Human brain immunohistochemistry
A single postmortem PMSE brain of a 7-month old female was procured from the Clinic
for Special Children (Lancaster, Pennsylvania, USA). Cortical dysplasia and focal
epilepsy syndrome cortex served as a non-PMSE epileptic control specimen (112). The
specimens were fixed in 4% paraformaldehyde (PFA), embedded in paraffin, and cut into
7-µm sections. Sections were probed with rabbit polyclonal anti-IRS1 (phospho
S636+S639; Abcam) and processed for immunohistochemistry as reported previously
(12).

Migration assay
mNPCs, MEFS, or human fibroblasts were plated on 6-well plates, chamber slides, or
laminin-coated cover slips, coated with poly-D-lysine (mNPCs; Sigma-Aldrich) or polyL-lysine (fibroblasts; Sigma-Aldrich) and cultured in complete mNPC or human
fibroblast media (specified above). Prior to the migration assay, cells were cultured for
24 hours in serum-deplete media (1 ml complete media : 4 ml basal media; DMEM/F12
for mNPCs or DMEM for fibroblasts; Gibco) to attenuate basal mTORC1 activity.
Serum-deplete media was maintained for the duration of the migration assay. Rapamycin
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(50 nM for mNPCs, 100 nM for fibroblasts) or p70S6Ki (10 µM) was applied for one
hour prior to and throughout the duration of the experiment. A 200-µl micropipette tip
was used to create a linear scratch across a confluent monolayer of cells (113). In PAK
inhibitor migration analysis, doses ranging from 1-10 µM IPA-3 (Tocris Bioscience)
were applied to Scram mNPCs for one hour prior to and throughout the duration of the
experiment. Confirmatory Western p-cofilin signaling analysis was performed using 10
mM IPA-3 for one hour and pre-treating with the ROCK inhibitor Y-27632 (10 µM;
BioVision) for 12 hours prior to cell lysis, to isolate PAK-dependent LIMK
phosphorylation.

Treatment with AraC
Mitotic inhibitor arabinofuranosyl cytosine (AraC, Cytosine β-D-Arabinofuranoside;
Sigma) was used to inhibit mitosis of migrating cells, and demonstrate that the migration
deficit seen with STRADA KD and rapamycin rescue were independent of any effects on
cell proliferation. Wildtype (WT) mNPCs were plated in serum-starve media in 6-well
plates, and pre-treated with AraC for 24 hours, after which a fresh dose of AraC was
applied for 0h, 15h, or 20h, in order to replicate the time course of the migration assay.
Cells were enzymatically de-adhered using 0.25% Trypsin-EDTA (Gibco) at each
indicated treatment time, and Trypan Blue (Sigma) was used to visualize and count cells
under light microscopy. The optimal effective anti-proliferative, non-apoptotic AraC
dose (20 µM) was applied to Scram and STRADA KD mNPCs for 24 hours prior to and
throughout the duration of the migration assay with rapamycin treatment.
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Video capture in migration assay
Migration of STRADA KD and Scram mNPCs was determined in chamber slides, within
a micro-incubator (model CSMI; Harvard Apparatus; at 37oC) on an inverted microscope
(Nikon TE300) equipped with a digital video camera (Evolution QEi; Media
Cybernetics) (114). Images were taken every 5 minutes in the phase-contrast channel for
20 hours. For each condition, three or four videos were taken across the scratch.

G:F Actin Assay
Cell lysates were prepared and actin was extracted and separated into G and F fractions
using differential ultracentrifugation and a G-actin/F-actin In Vivo Assay Kit
(Cytoskeleton), according to the manufacturer’s protocol. G and F actin fractions were
then electrophoresed on a 4-15% SDS-PAGE gel (Bio-Rad) and transferred onto a PVDF
membrane (Millipore) at 4oC overnight. G-actin/F-actin was assayed by Western blot
using rabbit anti-actin polyclonal Ab (1:500; Cytoskeleton).

In utero electroporation
We used in utero electroporation (IUE) to transfect ventricular zone/subventricular zone
(VZ/SVZ) cells in E14.0 C57BL/6J mouse embryos with GFP-tagged STRADA shRNA
plasmid (8 µg/µl), as described previously (115). A subset of pregnant dams was injected
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intraperitoneally with rapamycin (5 mg/kg, in vehicle solution composed of 5% PEG
400, 5% Tween 80, 0.9% NaCl in sterile water; LC Laboratories) daily from E15.0
through E18.0. Animals were sacrificed using CO2 overdose on E19.0, at which time
brains were extracted from the embryos, fixed in 4% PFA, cryoprotected in a sucrose
gradient, and frozen in Optimal Cutting Temperature solution (OCT, Tissue Tek). 20-µm
coronal sections were cut on a cryostat (Leica CM 1950), stained with Hoechst 33342
nuclear stain (0.0001 µg/µl; Invitrogen), and coverslipped in mounting media
(Fluoromount-G; Southern Biotech). Images were taken using a Leica DMI6000 B
fluorescent microscope with a Leica DFC360 FX camera.

Quantitative Analysis
Three independent observers quantified the percentage of GFP+ cells reaching the
cortical plate, using the Image-Pro Plus 7.0 (Media Cybernetics) automatic count
function for bright objects within an outlined region of interest, and this was verified by
hand count. Localization of the cortical plate (CP) was determined by relative nuclear
density.
In still-image migration assays, three independent coverslip scratches were made
per treatment condition per shRNA or disease condition, and three images were taken
across each scratch at each timepoint. A blinded observer recorded ten measurements per
image, yielding 90 measures per timepoint per condition (using Photoshop CS2; Adobe
or Image-Pro Plus 7.0). Migration distances were determined by subtracting the distance
between edges of the scratch at 15h from the distance at 0h and halving this value.
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For video migration assays, a blinded observer evaluated five representative
leading-edge cells per video, and measured the distance translocated and directional
angle at each 30-minute timepoint for the same cell, using Image-Pro Plus 7.0 software.
Migration distance for each cell over the 20 hours recorded was measured as the sum of
all 30-minute measures. Directional variance for each cell was calculated as the variance
in the set of directional angles. Greater directional variance was determined to indicate
reduced linear directionality.
In the Golgi compaction assay, a blinded observer used the outlining tool and area
measurement function in Image-Pro Plus 7.0 to define Golgi area in each cell. The
crescentic angle of Golgi subtended around the nucleus was calculated by measuring the
angle between two rays each passing through one end of the Golgi, with a vertex at the
center point of the nucleus.
To define relative levels of G and F actin, densitometric analysis was performed
using ImageJ (NIH) software. Band densities were standardized to background pixel
density for each image, and data are represented as a ratio of G:F actin (for STRADA
depletion conditions) or F:G actin (for LKB1 depletion) in the respective KD or KO
versus control.

Statistics
Data are presented in Table 1 as mean + s.e.m. Excel (Microsoft) and Prism 5
(GraphPad) software programs were used for statistical analysis. In all comparisons, a P
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value less than 0.05 was considered significant. Unpaired 2-tailed Student’s t tests were
performed to determine significance for all individual measures, and served as the sole
method of analysis for experiments set up as binary comparisons, including IUE and
video migration measures. For all still migration measures and measures of Golgi area
and crescentic angle, significance was determined by a 1-way ANOVA with a Bonferroni
correction for multiple comparisons in the migration assays or a Dunnett post-hoc
analysis to determine the extent of rapamycin or p70S6Ki rescue in the Golgi measures.

All animal experiments were approved by the Institutional Animal Care and Use
Committee of the University of Pennsylvania. All human studies were approved by the
Institutional Review Board of Lancaster General Hospital (Lancaster, Pennsylvania,
USA). Parents provided informed consent prior to their own and their children’s
participation.
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Results
STRADA KD in mNPCs causes an mTORC1 and p70S6K-dependent migration
defect in vitro
We hypothesized that loss of STRADA causes a primary failure of neural progenitor cell
migration. Thus, we developed a system to model cell migration in the setting of
STRADA loss in vitro. We established stably-transfected mNPC lines, using puromycinresistant STRADA shRNA (STRADA shRNA-puroR, STRADA KD) for STRADA KD
and control puromycin-resistant scrambled shRNA (Scram shRNA-puroR, Scram).
STRADA depletion (more than 90%) and enhanced mTORC1 signaling (evidenced by
enhanced phosphorylation of downstream effectors ribosomal S6 and 4EBP1 proteins) in
the STRADA shRNA-puroR line was confirmed by Western analysis (Figure 3.1A).
Cell migration in STRADA KD and Scram mNPC lines was defined in a
modified wound-healing assay previously described in fibroblasts (113). A 200-ml
micropipette tip was used to create a scratch gap in confluent mNPCs. The gap
established opposing migratory leading edges so that measurements of cell migration
across the gap could be determined from the time of the scratch (0h) to 15 hours later
(15h). STRADA KD significantly reduced the gap closure at 15h, compared with Scram
cells, suggesting that STRADA KD impairs mNPC migration. We next show that the
effect of STRADA KD on gap closure can be rescued by the mTORC1 inhibitor
rapamycin (50 nM) at 15h (Figure 3.1B,D; Table 3.1). In order to rule out the possibility
that STRADA KD or rapamycin treatment produced differences in gap closure by
altering cell mitotic rate, we applied the mitotic inhibitor arabinofuranosyl cytosine
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(AraC, 20 µM) 24 hours prior to and during the course of migration. Following AraC
treatment, STRADA-deplete mNPCs continued to exhibit a significant migration deficit,
rescued by rapamycin, suggesting that STRADA’s role in mNPC migration is mTORC1dependent and not altered by changes in cell mitosis (Table 3.1).
To further define the signaling mechanisms causing impaired migration, we next
hypothesized that altered migration observed in STRADA KD mNPCs was mediated by
the mTORC1 substrate p70S6K, due to its putative association with actin dynamics and
cell migration (116, 117). mNPCs were treated with a novel selective p70S6K inhibitor
(p70S6Ki), PF-4708671 (72). P70S6Ki (10 µM) was applied one hour prior to the
initiation of the assay (-1h) and maintained until 15h. Treatment with p70S6Ki provided
a full rescue of the STRADA KD-associated migration defect and resulted in a
significantly greater distance migrated by STRADA KD cells at 15h (Figure 3.1C-D,
Table 3.1). Thus, altered migration of STRADA KD mNPCs is mediated through a
p70S6K-dependent mechanism.

STRADA KD impairs mNPC pathfinding
We next analyzed the distance migrated and directionality of individual STRADA KD
mNPCs in real time using video time-lapse microscopy. Movement of multiple,
individual STRADA KD and Scram mNPCs was captured every five minutes for 20
hours. A blinded observer evaluated five representative leading-edge cells per video and
measured for each cell the distance traveled and direction angle relative to a unit circle,
over each 30-minute epoch. Total distance traveled for each cell was calculated as the
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sum of all distances measured over 20 hours, and directionality was calculated as the
variance of the set of angles over that time period.
While most Scram cells moved forward in a linear fashion, STRADA KD cells
moved in divergent, non-linear directions, often oriented away from the opposing cell
front (Figure 3.2A). In fact, to our surprise, STRADA KD mNPCs translocated a greater
overall distance than Scram cells (Figure 3.2B, Table 3.1). However, compared to
Scram cells, STRADA KD resulted in a profound impairment in directionality, with
STRADA KD mNPCs exhibiting significantly greater directional variance than controls
(Figure 3.2D, Table 3.1). STRADA KD mNPCs migrated on average 1.5-fold greater
distance and exhibited a nearly 3-fold increase in directional variance compared to Scram
cells. Thus, in the absence of functional STRADA, individual mNPCs lose the ability to
follow a linear migratory pathway. These results demonstrate that STRADA plays a
pivotal role in establishing linear directionality and pathfinding of migrating mNPCs.

STRADA mediates mNPC pathfinding via mTORC1 signaling
We next hypothesized that STRADA regulates mNPC pathfinding via mTORC1
inhibition. Indeed, rapamycin treatment significantly reduced total distance migrated by
STRADA KD cells, as well as diminished directional variance compared with untreated
STRADA KD mNPCs. (Figure 3.2C,E; Table 3.1). Overall, rapamycin enhanced linear
directionality, and enabled more uniform migration of STRADA KD mNPCs. Thus,
STRADA drives migrating cell directionality by inhibiting mTORC1 signaling.
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STRADA regulates mNPC polarization through mTORC1/p70S6K signaling
Since STRADA KD impairs mNPC directionality, and since pathfinding depends in large
measure on appropriate establishment of cell polarity, we next investigated whether
STRADA KD alters mNPC polarity. It is well established that the Golgi apparatus is
compacted and localized forward of the nucleus in the direction of migration, i.e., the
cell's leading edge, during active motility of fibroblasts and neurons (118) and that cell
polarity depends on intact structure, function, and localization of the Golgi apparatus
(119) (69, 73). Therefore, we used Golgi compaction as a bioassay to measure
polarization of mNPCs.
Ten hours after initiation of migration, cells were fixed and immunostained for
the Golgi marker GM130, and co-labeled with Hoechst nuclear stain and phalloidin for
actin cytoskeleton visualization. A blinded observer measured Golgi area and the
crescentic angle subtended by the Golgi around each cell’s nucleus. We hypothesized
that if STRADA KD disrupted neural progenitor polarization, STRADA-deplete mNPCs
would exhibit Golgi dispersion (greater area and crescentic angle). In fact, STRADA KD
significantly increased Golgi area and the crescentic angle of the Golgi around the
nucleus compared with Scram cells (Figure 3.3A-B,E-F; Table 3.1). In a separate
experiment, Scram and STRADA KD mNPCs were treated with rapamycin (50 nM) or
p70S6Ki (10 µM). Enhanced Golgi area and crescentic angle in STRADA KD mNPCs
was partially rescued with rapamycin and fully rescued with p70S6Ki treatment (Figure
3.3C-F; Table 3.1). Thus, reduced Golgi compaction associated with STRADA
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depletion suggests that STRADA plays a critical role in polarizing migrating mNPCs, in
an mTORC1- and p70S6K-dependent manner.

STRADA promotes inhibitory cofilin phosphorylation through IRS1
We hypothesized that STRADA contributes to cell polarization and pathfinding in
mNPCs via p70S6K phosphorylation of IRS1, a recognized downstream target of
p70S6K that signals to the actin cytoskeleton machinery via cofilin (67, 120). Indeed,
Western analysis demonstrated that STRADA KD in mNPCs led to enhanced P-IRS1
levels (Figure 3.4B). To confirm our findings in human brain, we investigated the level
of IRS1 phosphorylation in PMSE patient cortex and found that P-IRS1 was enhanced in
PMSE compared with control cortex (Figure 3.4A). Next, we evaluated the cofilin
signaling pathway, which is modulated by IRS1 signaling via PAK1 and LIMK. In the
setting of STRADA depletion and enhanced inhibitory phosphorylation of IRS1, PAK1
phospho-activation (indicated by autophosphorylation at Ser 144 residue) was reduced,
leading to diminished LIMK phosphorylation and diminished phospho-inhibition of
cofilin (Figure 3.4B). To validate p70S6K/IRS1 as a mechanistic link between mTORC1
and the cofilin signaling pathway, we evaluated the phosphorylation status of IRS1 and
cofilin in a subset of STRADA KD mNPCs treated with p70S6Ki (10 µM). Inhibition of
p70S6K rescued enhanced IRS1 phosphorylation as well as diminished cofilin
phosphorylation in the STRADA-deplete cells, indicating that STRADA’s role in cofilin
signaling operates through p70S6K/IRS1 (Figure 3.4C).
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Because signaling from IRS1 to LIMK/cofilin occurs via PAK1, which in normal
cells is activated during migration, we hypothesized that pharmacological blockade with
a PAK1 inhibitor would attenuate mNPC motility. Indeed, application of the PAK
inhibitor IPA-3 (121) caused a migration deficit in Scram mNPCs similar to that seen in
the STRADA KD line, and reduced distance migrated in a dose-dependent manner
(Figure 3.4D, Table 3.1). Using a Rho kinase (ROCK) inhibitor (Y-27632) (122) to
attenuate compensatory LIMK phosphorylation in the absence of PAK1 activation, we
further show that PAK1 inhibition results in a decrease in phosphorylated cofilin in
Scram mNPCs, mirroring the signaling pattern of STRADA KD (Figure 3.4E). These
data demonstrate that STRADA inhibits mTORC1/p70S6K activity, resulting in active
IRS1 and consequent PAK1 phosphorylation of LIMK, which phosphorylates and
inhibits cofilin (mechanism proposed in Figure 3.5). STRADA inhibition of cofilin
promotes migrating cell linear directionality. Conversely, loss of STRADA leads to
enhanced IRS1 phosphorylation, reduced phospho-inhibition of cofilin, and impaired
motility.

STRADA and LKB1 exhibit dissociable effects on cofilin
Loss of LKB1 in cancer cell lines as well as in Lkb1-null MEFs is associated with
enhanced cell migration, in direct contrast to our results demonstrating impaired
migration in STRADA KD mNPCs. Thus, since STRADA has only been defined
previously as an activator of LKB1 (1, 6-8, 14, 23), we investigated several signaling
nodes both upstream and downstream of PAK1 in Lkb1-/- versus Lkb1+/+ MEFs (19, 23),
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for comparison with signaling patterns in our STRADA KD mNPCs. In fact, in contrast
to STRADA KD mNPCs, Lkb1-/- MEFs exhibited distinct and opposite patterns of PAK1,
LIMK, and cofilin phosphorylation, with enhanced P-PAK1 (Ser 144), P-LIMK and Pcofilin, suggestive of activated PAK1 (Figure 3.4B). These results demonstrate that
phosphorylation patterns associated with STRADA versus LKB1 depletion diverge at the
level of PAK1, suggest opposing influences of STRADA and LKB1 on signaling to
cofilin, consistent with opposite functional effects of STRADA and LKB1 on cell
migration.

Fibroblasts from PMSE patients exhibit aberrant IRS1/cofilin signaling
We next hypothesized that the effects of STRADA loss on IRS1 and cofilin
phosphorylation in mNPCs would be replicated in human PMSE cells. Thus, we
generated fibroblasts from skin punch biopsy samples from control (STRADA+/+; n=1)
and PMSE (STRADA-/-; n=3) subjects (Figure 3.6A). Compared to control cells, PMSE
fibroblasts exhibit enhanced S6 and IRS1 phosphorylation and diminished cofilin
phosphorylation, directly corroborating the signaling mechanism defined in STRADA
KD mNPCs (Figure 3.4F). These results were in contrast to the phosphorylation profile
of cofilin seen in Lkb1-/- MEFs, suggesting a STRADA-specific effect.

PMSE patient fibroblasts exhibit a migration defect
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We next performed the wound-healing migration assay in human PMSE and control
fibroblasts as a strategy to further corroborate the effects of STRADA KD in mNPCs.
PMSE and control fibroblasts were treated with rapamycin (100 nM) or p70S6Ki (10
µM) throughout the duration of the assay (ending at 15h). The distance migrated by
PMSE fibroblasts was significantly reduced relative to control fibroblasts, and this effect
was reversed with rapamycin or p70S6Ki treatment, suggesting a dependence on
mTORC1/p70S6K signaling (Figure 3.6B-C, Table 3.1). Thus, both the signaling and
functional effects of STRADA loss identified in mNPCs are robustly replicated in human
PMSE cells. We then evaluated the effects of p70S6Ki treatment of these cells on the
phosphorylation status of S6 and IRS1, and found that inhibiting p70S6K in PMSE
fibroblasts reduces phosphorylation of both effectors, also consistent with our proposed
mechanism (Figure 3.6D). Importantly, parallel signaling patterns and migration deficit
phenotypes in STRADA KD mNPCs and PMSE fibroblasts demonstrate that our in vitro
murine data provide translational insights into PMSE pathogenesis and the role of
STRADA in human brain development.

STRADA and LKB1 differentially regulate actin polymerization
We hypothesized that if STRADA functions to regulate cofilin activity, loss of STRADA
should change the composition of actin structure. Notably, polymerized or filamentous
(F) actin plays a critical role in establishing polarity of migrating cells (73). To test this,
we measured the relative contents of depolymerized globular (G) versus polymerized F
actin in STRADA KD and Scram mNPCs using a differential centrifugation assay. As
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expected, in association with reduced cofilin phosphorylation in STRADA KD mNPCs,
the ratio of G:F actin was approximately 2.91 times greater in STRADA KD than in
Scram mNPCs (Figure 3.7A). Thus, loss of cofilin inhibition associated with STRADA
KD in migrating neurons disrupts actin polymerization and establishment of F actin. We
next performed the differential centrifugation actin assay on PMSE versus control
fibroblasts, and found that PMSE fibroblasts exhibit an approximately 12.59-fold greater
ratio of G:F actin than control cells (Figure 3.7B). We submit that STRADA promotes
the phosphorylation and inhibition of cofilin, enabling actin polymerization and
consequent migrating cell polarization and linear directionality. Importantly, these results
demonstrate that impaired actin polymerization is a common mechanism highly
associated with the absence of STRADA both in human PMSE fibroblasts and in
STRADA KD mNPCs. Interestingly, Lkb1-/- MEFs exhibited the opposite pattern, with a
predominance of polymerized actin. Compared with Lkb1+/+ MEF control cells, the Lkb1/-

line exhibited a 2.78-fold greater ratio of F:G actin (in contrast to the trend seen in

conditions of STRADA depletion), consistent with enhanced cofilin phosphorylation and
increased

migration

associated

with

LKB1

depletion

(Figure

3.7C).

Rapamycin prevents heterotopic neurons associated with STRADA KD in
developing cortex
Since STRADA modulates IRS1 signaling through mTORC1 inhibition, we
hypothesized that pharmacological mTORC1 inhibition could rescue aberrant cortical
lamination in a mouse PMSE model (12). STRADA shRNA knockdown (KD; GFP77

tagged shRNA plasmid targeting STRADA) by IUE on embryonic day 14 (E14) in the
mouse cortex results in heterotopic neurons in the VZ/SVZ that fail to migrate to the CP
by E19. Transfected pregnant dams were treated with daily intraperitoneal injections of
rapamycin (5 mg/kg) or vehicle control solution (0.9% saline) from E15 until sacrifice at
E19. While vehicle-treated pups exhibited a cortical malformation with the majority of
STRADA KD neurons failing to migrate into the CP at E19, rapamycin treatment
significantly rescued the cortical migratory defect and enabled STRADA KD neurons to
reach the CP (Figure 3.8, Table 3.1). These findings support a mechanistic link between
enhanced mTORC1 signaling and aberrant neuronal migration in PMSE.
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Discussion
We demonstrate that STRADA functions as pivotal regulator of polarity and
pathfinding in migrating neurons by signaling from IRS1 to cofilin and promoting actin
polymerization. Loss of STRADA in PMSE patient fibroblasts or following shRNA
knockdown in mNPCs leads to mTORC1 activation and enhanced phospho-inhibition of
IRS1 via p70S6K, which in turn diminishes PAK1 phospho-activation of LIMK.
Activated PAK1 phosphorylates and activates LIMK, which phosphorylates and inhibits
cofilin, promoting actin polymerization, an essential process in leading edge formation
and establishment of polarity in migrating neurons and fibroblasts (73, 123-125).
Reduced LIMK activation leads to diminished phospho-inhibition of cofilin and
enhanced actin depolymerization. Thus we submit that STRADA depletion disrupts
neuronal polarity and consequently, pathfinding and migration via effects on actin.
Detection of enhanced P-IRS1 in human PMSE cortex supports the hypothesis that
disruption of this signaling mechanism occurs in PMSE during brain development,
resulting in failed neuronal migration and consequent heterotopic neurons in the
subcortical white matter. The rescue of heterotopic neurons following STRADA KD with
rapamycin suggests dependence of PMSE phenotype on mTORC1-p70S6K signaling and
yields an important therapeutic target.
Our studies define STRADA as a critical modulator of mTORC1-p70S6K-IRS1
signaling in neural progenitor cells. The rescue of impaired migration with rapamycin
following STRADA KD in vitro and in vivo strongly supports an mTORC1-dependent
mechanism, further substantiated by rescue in vitro with an inhibitor of p70S6K, which
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reverses the phospho-inhibition of IRS1. p70S6K signaling has been identified as an
essential pathway in cell migration, contributing to cell motility and actin filament
remodeling (116). P-p70S6K phosphorylates IRS1, driving a decrease in PI3K-mediated
activation of the Rho GTPases Rac1 and Cdc42 and corresponding decrease in PAK1
activation, an effect associated with impaired cell migration in TSC2-depleted
fibroblasts, downstream of STRADA (66, 67, 126). TSC2-null MEFs exhibit impaired
cell motility and enhanced mTORC1 activation, suggesting a link between enhanced
mTORC1-p70S6K-IRS1 signaling and diminished cell motility (66). In our STRADA
KD studies, diminished downstream phospho-signaling through PAK1 and LIMK leads
to decreased cofilin phosphorylation and disrupted actin polymerization, evidenced by an
increase in the relative proportions of G to F actin, which is corroborated in PMSE
patient fibroblasts. In fact, the phenotype of STRADA KD in mNPCs is reminiscent of
cells expressing mutant PAK1, which exhibit disrupted pathfinding (127).
Our findings of impaired cell migration in the setting of STRADA depletion are
in direct contrast to enhanced cell migration reported in LKB1 depletion models (128),
suggesting dissociable effects of LKB1 on cell migration in the presence or absence of
STRADA that shed light on these phenotypic differences. We thus propose a new model
for the interaction between STRADA and LKB1, wherein STRADA binding LKB1
modulates LKB1 to preferentially activate AMPK and therefore inhibit mTOR, providing
a downstream activation of PAK1 via IRS1, PI3K, and Rho GTPases. When STRADA is
present, PAK1 activation through the mTORC1 pathway is dominant and cofilin is
phosphorylated and inhibited, favoring actin polymerization and establishment of
migrating cell polarity. In contrast, in the absence of STRADA, PAK1 is inhibited dually,
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through enhanced mTORC1 signaling and consequent inhibition of IRS1/p70S6Kdependent activation of PAK1, and possibly through direct LKB1 inhibition of PAK1.
Indeed, a recent study has defined a direct inhibitory link between LKB1 and PAK1,
through phosphorylation at PAK1 Thr 109 (128). In the absence of LKB1, the
predominant effect is PAK1 activation, as a consequence of removing LKB1 direct
inhibition of PAK1. In this case, cofilin phospho-inhibition by activated LIMK is
increased, resulting in enhanced actin polymerization and increased migration. Thus, we
propose that under normal circumstances, STRADA binding to LKB1 favors PAK1
activation to drive polarity and pathfinding in migrating neurons. This is consistent with
previous studies demonstrating that induction of STRADA in intestinal epithelial cells
was sufficient to cause cell-autonomous establishment of polarity in an LKB1-dependent
manner (71). Interestingly, a recent study has demonstrated that overexpressing
STRADA in the setting of LKB1 loss in cancer cells could activate PAK1 and induce cell
polarization (110). The dependence of this effect on mTORC1/p70S6K and IRS1
signaling, as suggested by our work, will need to be considered in further experiments. In
a previous study, we have shown that STRADA depletion is associated with a
predominance of LKB1 in the nucleus, consistent with a role for STRADA in nucleocytoplasmic transport of LKB1 (7, 8, 12). Because each component of our defined
signaling mechanism (Figure 3.5) can function in nucleus as well as cytoplasm, further
studies are needed to determine the particular effects of subcellular localization on the
interaction between LKB1 and PAK1, and the consequent polymerization state of actin
(1, 129).
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Using PMSE as a model disease, we have defined a novel mechanism linking
STRADA and mTOR signaling to actin assembly, cell polarization, neuronal migration,
and cortical development, which may be functional in other mTORC1-associated
neurodevelopmental disorders. We propose that STRADA plays a critical role in neural
progenitor cell migration during cortical development, and likely accounts for heterotopic
neurons in PMSE. In the future, targeting functional nodes along the STRADA/mTORC1
cascade could offer plausible therapeutic approaches to inhibit aberrant IRS1/cofilin
signaling in other mTORC1-associated neurodevelopmental disorders such as TSC or
autism-macrocephaly syndrome.
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Table 3.1. Data Quantification and Statistical Measures for STRADA Migration

S.E.M.

Unit Measured

Comparison

p-value

n

Condition

Mean

Cell Type
3.67 µm
4.42 µm
9.03 µm

STRADA KD-untreated vs. STRADA KD-Rapa

<0.00001

wells,
wells,
wells,
wells,
wells,
wells,

640
600
300
360

90
90
90
90
90
90

90
90
90
90
90
90

measures
measures
measures
measures
measures
measures

measures
measures
measures
measures
measures
measures

Vehicle Control vs. Rapamycin-treated

CTL vs. PMSE-untreated
PMSE-untreated vs. PMSE-Rapa
PMSE-untreated vs. PMSE-p70S6Ki

Scram-untreated
Scram-untreated
Scram-untreated
Scram-untreated
Scram-untreated

Scram-untreated
Scram-untreated
Scram-untreated
Scram-untreated
Scram-untreated

vs.
vs.
vs.
vs.
vs.

vs.
vs.
vs.
vs.
vs.

STRADA KD-untreated
Scram-IPA-3 (1 µM)
Scram-IPA-3 (2.5 µM)
Scram-IPA-3 (5 µM)
Scram-IPA-3 (10 µM)

STRADA KD-untreated
Scram-IPA-3 (1 µM)
Scram-IPA-3 (2.5 µM)
Scram-IPA-3 (5 µM)
Scram-IPA-3 (10 µM)

0.000051

0.0019
<0.00001
<0.00001

<0.00001
0.07
0.00022
<0.00001
<0.00001

0.000029
0.0015
<0.00001
<0.00001
<0.00001

Treatment

Corresponding Figure
313.62
244.77
268.4

<0.00001
0.000016

Scram
Untreated
STRADA KD Untreated
Rapamycin (50 nM)
3.61 µm
2.9 µm
2.51 µm

Scram vs. STRADA KD-untreated
STRADA KD-untreated vs. STRADA KD-Rapa

mNPCs

135.99
113.66
134.35

3 wells, 90 measures
3 wells, 90 measures
3 wells, 90 measures

1B

Scram
Untreated
STRADA KD Untreated
p70S6Ki (10 µM)

<0.00001
0.74

mNPCs

Scram vs. STRADA KD

<0.00001

measures
measures
measures
measures

20 cells
15 cells

STRADA KD-untreated vs. STRADA KD-Rapa

90
90
90
90

20 cells
20 cells

degrees
degrees
degrees
degrees

3
3
3
3
3
3

wells,
wells,
wells,
wells,
wells,
wells,

measures
measures
measures
measures

0.0001

Scram vs. STRADA KD-untreated
Scram vs. STRADA KD-p70S6Ki

1C

11.66
13.13
15.68
20.83

20 cells
15 cells

2C

3 wells, 90 measures
3 wells, 90 measures
3 wells, 90 measures

Supplement to Fig. 1
mNPCs
Data for AraC Migration

560.05
534.61
421.47
564.65
26.63 µm
64.13 µm

20 cells
20 cells

0.14
<0.00001
<0.00001
0.2

WT
AraC only
Scram
AraC only
STRADA KD AraC only
STRADA KD AraC+Rapamycin (50 nM)
508.59
688.74
23.89 µm
21.98 µm

<0.00001

Scram
Untreated
STRADA KD Untreated
397.46
348.31

92.93 degrees^2
129.39 degrees^2

WT-AraC vs. Scram AraC
Scram-AraC vs. STRADA KD-AraC
STRADA KD-AraC vs. STRADA KD-AraC+Rapa
Scram-AraC vs. STRADA KD-AraC+Rapa

mNPCs

STRADA KD Untreated
STRADA KD Rapamycin (50 nM)
784.88
2050.1

111.08 degrees^2
84.12 degrees^2

Scram vs. STRADA KD

mNPCs

Scram
Untreated
STRADA KD Untreated
2254.38
1481.8

wells,
wells,
wells,
wells,

mNPCs

STRADA KD Untreated
STRADA KD Rapamycin (50 nM)

<0.00001
0.00204
<0.00001
0.67

3
3
3
3

2D

mNPCs

Scram vs. STRADA KD-untreated
STRADA KD-untreated vs. STRADA KD-Rapa
STRADA KD-untreated vs. STRADA KD-p70S6Ki
Scram vs. STRADA KD-p70S6Ki
1.86
2.35
2.56
2.8

µm
µm
µm
µm
µm
µm

3
3
3
3
3
3

90
90
90
90

cells
cells
cells
cells
98.56
112.82
104.93
104.86

3.79
7.48
5.51
3.77
4.26
4.64

µm
µm
µm
µm
µm
µm

wells,
wells,
wells,
wells,

640
600
300
360

Scram
STRADA KD Untreated
STRADA KD Rapamycin (50 nM)
STRADA KD p70S6Ki (10 µM)

142.57
178.56
148.55
129.99
124.86
66.34

3.61
7.36
5.65
4.82
4.49
5.39

3
3
3
3

µm^2
µm^2
µm^2
µm^2

mNPCs

Untreated
Untreated
IPA-3 (1 µM)
IPA-3 (2.5 µM)
IPA-3 (5 µM)
IPA-3 (10 µM)

256.71
315.5
298.57
282.34
260.5
179.88

µm
µm
µm
µm

<0.00001
0.037
0.033

mNPCs

STRADA KD
Scram
Scram
Scram
Scram
Scram

Untreated
Untreated
IPA-3 (1 µM)
IPA-3 (2.5 µM)
IPA-3 (5 µM)
IPA-3 (10 µM)

6.97
6.14
9.54
7.58

Scram vs. STRADA KD-untreated
STRADA KD-untreated vs. STRADA KD-Rapa
STRADA KD-untreated vs. STRADA KD-p70S6Ki

mNPCs

STRADA KD
Scram
Scram
Scram
Scram
Scram

231.71
201.55
269.29
285.75

cells
cells
cells
cells
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Figure 3.1. STRADA KD is associated with migration deficit in mNPCs, in an
mTORC1- and p70S6K-dependent manner.
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Figure 3.1. STRADA KD is associated with migration deficit in mNPCs, in an
mTORC1- and p70S6K-dependent manner. A, STRADA depletion and enhanced
mTORC1 signaling in a stably-transfected STRADA shRNA-puroR (STRADA KD)
mNPC line used for migration assays. STRADA KD cells exhibit reduced expression of
STRADA and enhanced phosphorylated S6 (P-S6) and 4EBP1 (P-4EBP1) protein levels,
indicating mTORC1 activity, relative to Scram shRNA-puroR (Scram) control cells.
GAPDH was used as an internal loading control. B, Untreated STRADA KD mNPCs
exhibit reduced migration in a wound-healing migration assay, relative to Scram mNPCs.
n = 3 wells, 90 measures per condition at each timepoint, ***P < 0.001. Treatment with
either rapamycin or C, p70S6Ki significantly increases the distance migrated by
STRADA KD cells, confirming that STRADA regulates mNPC migration through
mTORC1/p70S6K signaling. n = 3 wells, 90 measures per condition at each timepoint,
***P < 0.001. D, Representative images depict gap closure in each transfection (Scram
or STRADA KD) and treatment (Untreated, Rapa, and p70S6Ki) condition from the time
the scratch is made (0h) to the endpoint of measurement (15h). Scale bar: D, 250 µm.
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Figure 3.2. STRADA-deplete migrating mNPCs exhibit impaired linear directionality. A,
The migratory paths of individual cells recorded every 30 minutes for 20 hours in each
panel are represented by individual colors, and white arrows indicate the composite
migration vectors of each cell. Scram mNPCs migrate in a predominantly uniform linear
manner to close the gap created in the wound-healing migration assay. STRADA KD
mNPCs migrate in a haphazard fashion without consistent linear direction. Treatment
with rapamycin restores linear directionality in these cells. B-E, Quantitative analysis
reveals a significant increase in B, overall distance migrated as well as D, directional
variance in STRADA KD mNPCs. C,E, These effects are both attenuated with
rapamycin treatment. n = 15 cells for untreated STRADA KD, 20 cells for each other
condition, ***P < 0.001. Scale bar: A, 100 µm.
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Figure 3.3. STRADA depletion in mNPCs impairs polarization capacity, evidenced by
Golgi dispersion. A, Representative immunofluorescent images demonstrate compaction
of Golgi (indicated by GM130) forward of the nucleus toward the leading edge in
migrating Scram mNPCs, and B, dispersion of the Golgi around the nucleus with failure
to establish cell polarity in migrating STRADA KD mNPCs. Golgi compaction is largely
restored in STRADA KD cells with C, rapamycin or D, p70S6Ki treatment. White
arrowheads indicate representative Golgi bodies in each panel. E, Quantification of Golgi
area as a measure of compaction reveals significantly increased area in STRADA KD
compared with Scram mNPCs, attenuated with rapamycin or p70S6Ki treatment. n = 640
cells for Scram, 600 cells for untreated STRADA KD, 300 cells for Rapa-treated
STRADA KD, 360 cells for p70S6Ki-treated STRADA KD, ***P < 0.001, **P < 0.01.
F, Similarly, quantification of crescentic angle subtended by Golgi around the nucleus
reveals greater dispersion (larger angle) in STRADA KD mNPCs, attenuated with
rapamycin or p70S6Ki treatment. Taken together, these results suggest that STRADA
mediates migrating mNPC capacity to polarize, in an mTORC1-/p70S6K-dependent
manner. n = 640 cells for Scram, 600 cells for untreated STRADA KD, 300 cells for
Rapa-treated STRADA KD, 360 cells for p70S6Ki-treated STRADA KD, ***P < 0.001,
*P < 0.05. Scale bar: (in A) A-D, 50 µm.
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Figure 3.4. STRADA regulates cell migration through IRS1 signaling to cofilin,
dissociable from LKB1’s regulation of cofilin.
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Figure 3.4. STRADA regulates cell migration through IRS1 signaling to cofilin,
dissociable from LKB1’s regulation of cofilin. A, PMSE patient cortex exhibits enhanced
expression of P-IRS1 relative to control epileptic cortex, linking aberrant mTORC1
signaling associated with STRADA loss in the brain to the cofilin signaling pathway, via
IRS1. B, Western analysis reveals enhanced phosphorylation of S6 and IRS1, and
diminished autophosphorylation of PAK1 (Ser 144) and phosphorylation of LIMK and
cofilin, in STRADA KD mNPCs. In contrast, the phosphorylation pattern of Lkb1-/MEFs diverges from that of STRADA KD at the level of PAK1. Lkb1-/- MEFs exhibit
enhanced phosphorylation of S6 and IRS1, but also enhanced phosphorylation of PAK1,
LIMK, and cofilin, indicating dissociable roles for STRADA and LKB1 in the cofilin
signaling pathway. GAPDH serves as an internal loading control. C, p70S6Ki rescues
aberrant IRS1/Cofilin signaling in STRADA KD mNPCs. Compared with Scram control
cells, untreated STRADA KD mNPCs exhibit enhanced phosphorylation of S6 and IRS1,
with diminished inhibitory phosphorylation of cofilin. Treatment with p70S6Ki rescues
these effects, indicating a p70S6K dependence of this mechanism. GAPDH serves as an
internal loading control. D, Application of the PAK inhibitor IPA-3 at increasing doses
(1-10 µM) in Scram mNPCs produces a migration defect at 10h and 20h that mimics that
caused by STRADA KD, implicating PAK1 as a key operator in this effect, consistent
with the signaling mechanism proposed. n = 3 wells, 90 measures per condition at each
timepoint, ***P < 0.001. E, Reduced cofilin phosphorylation caused by PAK inhibition
with ROCK inhibition. To isolate the effects of PAK inhibition with IPA-3 treatment on
cofilin phosphorylation, ROCK inhibitor Y-27632 (10 µM) was applied 12 hours prior to
1-hour treatment with IPA-3 (10 µM). ROCK inhibition alone (R) reduces cofilin
phosphorylation relative to untreated cells (U), and PAK inhibition (R+P) provides
further reduction, indicating an independent effect of PAK on cofilin phosphorylative
inhibition. GAPDH serves as an internal loading control. F, PMSE patient fibroblasts
(PMSE; STRADA-/-) exhibit enhanced phosphorylation of S6 and IRS1, and diminished
phosphorylation of cofilin, relative to control (CTL; STRADA+/+) fibroblasts, supporting
the mechanism established in STRADA KD mNPCs. GAPDH serves as an internal
loading control. Scale bars: A, 50 µm (top), 10 µm (bottom).
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Figure 3.5. We propose that STRADA inhibits mTORC1/p70S6K, which promotes
Rac1/Cdc42 activation of PAK1 through P-IRS1/PI3K signaling, activating LIMK, and
inhibiting cofilin. STRADA-dependent phosphorylative inhibition of cofilin promotes
actin polymerization, which enables migrating cells to polarize by establishing an F-actin
based leading edge to drive linear directionality. LKB1 independently phosphorylates
and inhibits PAK1, producing the opposite pattern of phosphorylation at the level of and
downstream of this node as a consequence of LKB1 versus STRADA depletion.
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Figure 3.6. PMSE fibroblasts exhibit enhanced mTORC1/p70S6K activity and IRS1
phosphorylation and impaired migration, rescued with mTORC1 or p70S6K inhibition.
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Figure 3.6. PMSE fibroblasts exhibit enhanced mTORC1/p70S6K activity and IRS1
phosphorylation and impaired migration, rescued with mTORC1 or p70S6K inhibition.
A, Enhanced mTORC1 activity in PMSE fibroblasts. Western analysis performed on
control (CTL; STRADA+/+), heterozygous STRADA (HET; STRADA+/-), and PMSE
patient (PMSE; STRADA-/-) fibroblasts reveals enhanced P-S6, indicative of mTORC1
activity level, in HET compared to CTL fibroblasts, and further enhanced P-S6 in PMSE
fibroblasts. Each band represents a fibroblast line derived from a separate donor.
GAPDH serves as an internal loading control. B, In a wound-healing migration assay,
untreated PMSE fibroblasts demonstrate impaired migration at 15h, compared with
controls, corroborating the deficit associated with STRADA KD in mNPCs. C, PMSE
fibroblast migration is fully rescued by treatment with rapamycin or p70S6Ki. n = 3
wells, 90 measures per condition at each timepoint, ***P < 0.001, **P < 0.01. D,
p70S6K inhibition reduces enhanced S6 and IRS1 phosphorylation in PMSE fibroblasts.
Western analysis was used to quantify P-S6 and P-IRS1 in Control (CTL) and PMSE
patient (PMSE) fibroblasts, with (P) and without (U) p70S6Ki treatment. Untreated
PMSE fibroblasts exhibit greater P-S6 and P-IRS1 than CTL cells, and these effects are
attenuated with p70S6K inhibition, suggesting the efficacy of this mechanism as a
potential therapeutic approach. GAPDH serves as an internal loading control. Scale bar:
B, 250 µm.
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Figure 3.7. STRADA and LKB1 differentially regulate actin dynamics. A, Analysis of G
and F actin fractions reveals a 2.91-fold greater G:F ratio in STRADA KD compared
with Scram mNPCs, suggesting diminished capacity of cells to polymerize actin in the
absence of STRADA, consistent with enhanced cofilin activity. B, Actin analysis reveals
that PMSE fibroblasts exhibit a 12.59-fold enhanced G:F actin ratio compared with
controls, supporting the actin-based mechanism of aberrant migration proposed in
mNPCs and confirming this STRADA-specific role in actin polymerization across
different cell types, fibroblasts in addition to mNPCs. C, In contrast to STRADAdepleted mNPCs and PMSE fibroblasts, Lkb1-/- MEFs show the opposite pattern of actin
polymerization, with a 2.78-fold greater F:G ratio compared with Lkb1+/+ controls,
consistent with diminished cofilin activity.
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Figure 3.8. Inhibition of mTORC1 with rapamycin rescues the cortical lamination defect
associated with STRADA KD in the developing mouse brain. A-B, Vehicle-(0.9% saline)
injection does not alter cortical lamination defect at E19 induced by IUE transfection
with GFP-shRNA STRADA at E14. The majority of transfected cells remain in the
ventricular/subventricular zone (VZ/SVZ) and fail to reach the cortical plate (CP). C-D,
Rapamycin treatment of GFP-shRNA STRADA transfected animals from E15 to E18
prevents the laminar defect, and the majority of GFP+ cells reach the CP by E19. E,
Percentage of GFP-shRNA STRADA transfected cells reaching the CP at E19 following
rapamycin (Rapa) versus saline (Vehicle) treatment. ***P < 0.001. White arrowheads
indicate regions of GFP+ cells in each panel. Scale bar: (in A) A-D, 100 µm.
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CHAPTER 4

GENERATING A TRANSGENIC MOUSE MODEL OF PMSE
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PMSE patients present with intractable, multifocal epilepsy, starting in infancy
(61). Similarly, seizures are a common phenotypic manifestation of TSC, often
presenting in association with cortical tubers (29, 130, 131). In order to most effectively
model PMSE and investigate the role of STRADA in cortical development and epilepsy,
we are generating de novo a STRADA knockout (KO) mouse, in collaboration with Penn
Transgenic Facility.
We designed a transgenic floxed construct to replicate the deletion seen in PMSE
patients, with loxP sequences flanking exons 9-13 of the STRADA gene, which shares a
high degree of homology between mice and humans. In humans, this deletion results in a
lack of STRADA expression, producing an unstable variant of the protein (5, 12). Our
construct was transformed into embryonic stem (ES) cells generated from a C57BL/6
mouse, neomycin selection was applied, and resulting clones were confirmed to carry the
transgene via Southern analysis (Figure 4.1). The transformed ES cells were injected
into the blastocyst of a BALB-C albino mouse, and chimeric mice were generated, with
white fur indicating BALB-C background and black fur indicating the presumed
percentage of transgenic C57BL/6 carriage (for a diagram of this process, see Figure
4.2). Chimeric males with >75% black fur were mated to wildtype (WT) C57BL/6
females, and black F1 offspring were selected from agouti littermates and genotyped
using Southern analysis. We confirmed carriage of the STRADA KO transgene in two F1
offspring (STRADA+/fl), which we are breeding to generate a KO line (Figure 4.3).
Subsequent generations are evaluated for carriage of the transgenic floxed STRADA allele
through PCR detection of the neomycin resistance gene (NeoR) (Figure 4.4). Carriers are
then evaluated for heterozygosity or homozygosity through Southern analysis.
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Homozygous floxed mice (STRADAfl/fl) will be mated to Cre recombinase-expressing
(Cre) mice to yield the knockout (STRADAfl/fl;Cre+/- or STRADAfl/fl;Cre+/+), and
homozygous floxed mice not mated to Cre partners will be used as controls
(STRADAfl/fl;Cre-/-) (See Figure 4.5 for a schematic). If our KO mouse is non-viable, we
will create a conditional KO by mating the STRADAfl/fl mouse to a nestin promoter-driven
or drug-inducible promoter-driven Cre mouse. Additionally, we will perform focal KO in
cortex using IUE with a Cre plasmid in the STRADAfl/fl mice not mated to Cre partners, in
order to assess specifically the effects of STRADA gene KO in the developing brain, in a
cell-autonomous manner.
We anticipate that focal KO in the STRADAfl/fl mice will provide an effective way
to evaluate the implications of failed neuronal migration in cortical epileptogenesis and
thus model seizures in PMSE. Bai and colleagues demonstrated that knockdown of
Doublecortin (DCX), a microtubule-associated protein that plays a key role in migration,
using RNAi in IUE results in a subcortical band heterotopia (SBH) (132). Interestingly,
this is associated with aberrant neural firing patterns in the region of cortex overlying the
SBH. Calcium imaging recording of neurons in the cortical area of failed migration
revealed that these cells display both greater activity and greater co-activity, indicating
enhanced synchronization, suggestive of epileptogenic activity (133). Preliminary
electrophysiological analysis using calcium imaging in slice preparations from our IUEgenerated STRADA KD mice suggests that STRADA loss is associated with regional
hyperactivity in cortical areas overlying retention of transfected cells in VZ/SVZ.
Particularly in a high-potassium (5.5 mM K+) artificial cerebrospinal fluid (aCSF)
solution, we found a pattern similar to that generated by DCX knockdown, of enhanced
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neural firing and neural synchronicity, in the cortical area experiencing failed migration
of STRADA KD cells (Figure 4.6). Since we have demonstrated that STRADA
depletion impairs neuronal migration (see Chapter 3), and since appropriate neuronal
migration during development is critical to the establishment of effective cortical
networks, we hypothesize that this mechanism may account at least in part for the severe
epilepsy experienced by patients with PMSE (108, 133). Evaluation of behavioral
patterns and neural activity in the STRADA KO animals will provide an ideal platform
for investigation of this mechanism.
With the generation of a STRADA KO mouse, we will be able to evaluate more
effectively the phenotype associated with STRADA loss and test multiple therapeutic
options. Lifespan, head circumference, brain and body weights, metabolic panels, and
behavioral phenotype will be evaluated in this strain. A likely epileptic phenotype will be
assessed through video/EEG recording and calcium imaging of cortical and hippocampal
slice preparations. Additionally, it will be important to determine the capacity for
treatment with rapamycin and other mTOR inhibitors. Immunohistochemical analysis of
mTOR activity, cortical lamination, and neuronal differentiation profiles in KO brain
specimens will allow comparison between this model and the neuropathological patterns
seen in PMSE brain. Through our endeavors, we hope to delineate the role of STRADA
in cortical development and epilepsy, and optimize biologically-targeted therapies for
patients with mTOR-associated neurodevelopmental disorders, who are often refractory
to standard antiepileptic drugs.

98

Figure 4.1. Southern blotting confirms several clones of transformed ES cells to carry
the transgenic STRADA (STRADAfl) allele. Each column of bands represents DNA
extracted from a single clone of transformed ES cells and probed for STRADA. Higher
molecular weight bands (MW) represent wild-type (WT) STRADA, while lower MW
bands represent the transgenic floxed STRADA allele.
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Figure 4.2. Generation of a STRADA+/fl carrier mouse. As indicated in the diagram, we
replicated the deletion of STRADA exons 9-13, as seen in PMSE patients, to create the
transgenic STRADA allele, with this region flanked by loxP sites for later Cre
recombination. The transgene was engineered to carry this sequence as well as a
neomycin resistance (NeoR) gene, for selection. Embryonic stem (ES) cells were
extracted from the inner cell mass (ICM) of a C57BL/6 blastocyst, at 3 days postfertilization (DPF). These cells were cultured and transformed with the transgene.
Neomycin selection was applied, and viable colonies were expanded and genotyped to
confirm carriage of the transgene, via Southern blotting (SB). Transformed ES cells were
microinjected into the blastocyst of a BALB-C albino mouse and incorporated into the
developing embryo. This embryo was transferred to a host pseudopregnant female for
gestation and delivery. Resulting offspring expressed a chimeric phenotype, with white
fur color linked to non-transgenic cells from the BALB-C mouse, and black fur color
linked to transgenic ES cells transformed from the original C57BL/6 mouse.
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Figure 4.3. Southern blotting confirms F1 offspring to carry the transgenic STRADA
(STRADAfl) allele heterozygously. Each column of bands represents DNA extracted from
a single animal and probed for STRADA. Higher molecular weight bands (MW) represent
wild-type (WT) STRADA, while lower MW bands represent the transgenic floxed
STRADA allele (Floxed). “Female Black” and “Male Black” refer to mice with black fur
in the F1 generation, sired by P-generation chimeric males. Agouti mice served as
littermate controls, carrying only the WT STRADA allele.
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Figure 4.4. Polymerase chain reaction (PCR) indicates the presence of transgenic
STRADAfl allele in F2 animals. Each column represents DNA extracted from a separate
animal. Plus signs identify animals carrying the 493 bp neomycin resistance (NeoR) gene,
which indicates presence of the STRADA floxed transgene.
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Figure 4.5. Diagram outlines the process of generating a STRADA KO mouse from the
chimeric P/F0 generation. Refer to the text for details.
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Figure 4.6. Calcium imaging of the cortical plate layer 2/3 (CP 2/3) region overlying
heterotopic STRADA KD mNPCs reveals aberrant neuronal firing patterns. IUE was
used to transfect animals at embryonic day 14 (E14) with GFP-tagged STRADA shRNA,
to effect STRADA KD. At postnatal day 7 (P7), animals were sacrificed, and 350 µm
coronal sections were cut on a microtome. Fluorescent microscopy was used to define the
region of heterotopic GFP+ mNPCs located in the ventricular/subventricular zone
(VZ/SVZ), as well as the overlying CP 2/3 region, representing the appropriate
destination area to which the STRADA-deplete cells failed to migrate. Coronal slices
were bathed in artificial CSF (aCSF) solution or a potassium-supplemented (5 mM K+)
aCSF activating solution. In both solutions, the CP 2/3 region overlying the STRADA
KD heterotopia exhibited considerably higher levels of neuronal firing. This was
especially evident in the high-K+ solution (pictured), in which neurons in the CP
overlying the heterotopia exhibited evidence of epileptiform activity. Cells in this region
showed synchronous firing (indicated by yellow arrowhead) as well as burst spiking (red
arrow). A, Top panel demonstrates cortical neuronal firing outside the area of failed
migration in a focal STRADA KD animal at P7. B, Bottom panel demonstrates
enhanced cortical neuronal firing in the area of failed migration.
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CHAPTER 5

DISCUSSION AND CLINICAL TRANSLATION4

_______________________________________________________________________
4
The PMSE patient data reported here was originally published in Science Translational
Medicine, Vol. 5, No. 182, April 2013. Parker, W.E., Orlova, K.A., Parker, W.H.,
Birnbaum, J.F., Krymskaya, V.P., Goncharov, D.A., Baybis, M., Helfferich, J., Okochi,
K., Strauss, K.A., and Crino, P.B. Rapamycin Prevents Seizures After Depletion of
STRADA in a Rare Neurodevelopmental Disorder. Published by AAAS.
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So often, rare genetic disorders can offer key insights into the normal functioning
and role of a biological pathway based upon understanding the pathogenesis resulting
from what is lacked. Here, we have employed one such disorder, PMSE, to elucidate the
role of STRADA and mTOR signaling in cortical development. Although PMSE
provides us with a fortuitous opportunity to understand an important biological process,
we understand that this comes at a cost to those who suffer from the disorder without
effective treatment options. This chapter will summarize the conclusions of our work,
place STRADA into the larger context of mTOR-regulatory proteins, offer future
directions, and finally discuss the implications of our findings for treatment of PMSE and
other mTOR-associated neurodevelopmental disorders.
STRADA Plays a Critical Role in Cortical Development Through Directing Neuronal
Migration: A Summary of Our Results and Proposal of Future Studies
The landmark study by Puffenberger and colleagues, defining PMSE as a
STRADA mutation and describing the clinical and pathological phenotype of the disease,
identified periventricular nodules on MRI scans of two patients (61). Histopathological
analysis of tissue from a postmortem PMSE brain showed evidence of cytomegaly,
mTOR hyperactivity through enhanced P-S6, and the presence of heterotopic neurons in
the subcortical white matter, highly suggestive of failed neuronal migration (12, 61).
Further work in our lab was able to recapitulate the cytomegalic phenotype of PMSE
through shRNA knockdown of STRADA in mNPCs, and this effect could be prevented
with rapamycin treatment, indicating mTORC1 dependence (12). Additionally, we
showed that STRADA knockdown in vivo, results in clusters of heterotopic neurons
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within the murine post-natal VZ/SVZ, similar to heterotopia in PMSE (See Chapter 1)
(12). The VZ/SVZ heterotopic neurons expressed enhanced mTORC1 activation,
suggesting this as a possible mechanism. In a set of experiments outlined in Chapter 3,
we chose to investigate the hypothesis that aberrant mTORC1 signaling actually causes
aberrant cortical lamination in a STRADA-deplete experimental model. Additionally
based on the evidence of neuronal heterotopia in PMSE human and STRADA KD mouse
brain, we explored the hypothesis that STRADA affects cortical lamination through
directing neuronal migration.
First, we sought to determine whether a disruption in migration per se could
account for aberrant cortical lamination in the setting of STRADA loss. To do this, we
devised a minimalistic in vitro approach. We extracted mNPCs from neonatal murine
VZ/SVZ and transfected them with an shRNA targeting STRADA to induce STRADA
KD. We then subjected these cells to a wound-healing scratch migration assay, and saw a
significant decrease in distance migrated associated with STRADA KD. Importantly, this
effect could be prevented by treatment with rapamycin or p70S6Ki, indicating
dependence on mTORC1/p70S6K signaling. Next, we characterized this migration defect
as a disruption of neuronal pathfinding, using video microscopy, which revealed a loss of
directionality in migrating mNPCs with STRADA KD. This too was rescued by
rapamycin treatment, suggesting dependence of this effect on mTORC1. To corroborate
this finding, we used immunocytochemistry to evaluate the size and position of the Golgi
body relative to the nucleus of leading-edge migrating cells, and found an mTORC1/p70S6K-dependent disruption in cell polarity corresponding to STRADA KD. To
confirm mTORC1-dependence of failed neuronal migration in a mouse model, we
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subjected embryos to STRADA KD through IUE, and found that treatment with
rapamycin was able to rescue the capacity of transfected cells to reach their appropriate
destination in the CP.
We next hypothesized that STRADA regulates neuronal pathfinding through
modulating cofilin and actin dynamics, downstream of mTORC1. In a series of protein
quantification experiments, we defined phosphorylation profiles of several nodes in this
pathway consistent with enhanced IRS1 phosphorylation and a dysregulation of cofilin
signaling and consequent actin depolymerization in the setting of STRADA depletion.
Interestingly, profiling the phosphorylation status of nodes on this pathway in the setting
of LKB1 depletion in MEFs revealed a divergence at PAK1, consistent with a recent
report that LKB1 can directly phosphorylate and inhibit PAK1 at a separate
phosphorylation site (128), resulting in enhanced actin polymerization. This is also
consistent with a well-documented association of LKB1 loss with enhanced cell
migration in certain forms of metastatic cancers and in LKB1-null MEFs.
It is interesting to consider the mechanisms through which LKB1 depletion and
STRADA depletion might have opposite effects on cell migration. We speculate that
STRADA might in fact not be a universal activator of LKB1 as previously postulated (7).
We propose that it is likely that STRADA binding LKB1 activates the kinase specifically
toward phosphorylating certain downstream substrates, AMPK inclusive. When
STRADA is present, LKB1 activity toward the cofilin pathway is driven primarily
through mTOR, activating AMPK, inhibiting mTOR, activating PAK1, and inhibiting
cofilin, resulting in actin polymerization. In the absence of STRADA, however, the
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inhibitory influence of LKB1 on PAK1 appears stronger. We postulate that without
STRADA, LKB1 can not appreciably activate AMPK and thus can not inhibit mTOR,
resulting in a lack of PAK1 activation through the mTOR pathway. Secondarily, LKB1’s
direct phosphorylative inhibition of PAK1 goes unopposed, resulting in a second-hit
inhibition of PAK1, disinhibiting cofilin and depolymerizing actin, opposing effective
cell polarization and pathfinding. Further experiments, particularly employing mutation
of phosphorylation sites on PAK1 and AMPK in the presence and absence of STRADA
and LKB1 individually and together, will be necessary to delineate the specific
mechanism and test our hypotheses.
Evaluation of Our Proposed Mechanism of Cell Migration in PMSE: Summary of Our
Results in Patient Cells and Establishment of Preclinical Data
In order to be able to apply our proposed mechanism and role for STRADA in
neuronal migration to the human disease, we extracted fibroblasts from PMSE patients,
heterozygous parents, and controls. Western analysis of the phosphorylation profiles of
key nodes in our signaling pathway revealed a corroboration of our mNPC results.
Compared with control cells, PMSE fibroblasts exhibited enhanced phosphorylation of
mTORC1 targets S6 and IRS1, and diminished phosphorylative inhibition of cofilin.
Importantly, this was associated with actin depolymerization and a defect in cell
migration, rescued with rapamycin or p70S6Ki. To confirm the link from mTORC1
signaling into our defined pathway, we immunostained postmortem PMSE cortical tissue
for phosphorylated IRS1 and found enhanced P-IRS1 in PMSE compared with control
cortex.
109

Importantly, our results show that abnormal brain development in PMSE can be
attributed significantly to a defect in neuronal migration resulting from STRADA loss.
This defect results from enhanced mTORC1 signaling, as evidenced by rescue with both
mTORC1 inhibition through rapamycin and inhibition of its direct effector p70S6K.
Through our experiments in vitro and in vivo in mice, corroborated by parallel effects in
cells extracted from PMSE patients, we provide sufficient preclinical data for the
consideration of targeting the mTORC1/p70S6K pathway as a treatment strategy for
PMSE.
Modeling Epilepsy in PMSE: Future Directions
Our experiments extensively address the role of STRADA in neuronal migration,
and failed neuronal migration has been proposed as a mechanism for epileptogenesis
(108). Our preclinical data evaluating cortical activity in the region of failed neuronal
migration resulting from STRADA knockdown suggests that this may be an important
mechanism in our model as well, since this region exhibits neuronal hyperactivity and
enhanced synchronization (see Chapter 4). However, we have not yet addressed the
direct effects of STRADA depletion on altering the firing potential of individual neurons.
Recent studies by Filippi and colleagues have shown that STRADA’s binding partner
MO25 can induce an approximately 100-fold activation of SPAK/OSR1 kinases,
enhancing their ability to phosphorylate the ion cotransporters NKCC1, NKCC2, and
NKCC (134). Knockdown of MO25 inhibited phosphorylation of NKCC1 by
SPAK/OSR1, and this was rescued by MO25 re-expression. Alteration of NKCC1 and
NKCC2 expression can dramatically alter membrane potential and thus likelihood of a
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neuron to fire an action potential. In fact, it is precisely a change in the ratio of NKCC1
to NKCC2 membrane expression that is thought to change the response of early neurons
in the developing brain to GABA from excitation to inhibition, based on a switch from
predominantly intracellular to predominantly extracellular chloride concentrations (135).
Importantly, NKCC1 has recently been suggested as a potentially attractive
pharmacological target in epilepsy (136). Common loop diuretics, particularly
bumetanide, can be used to inhibit this transporter and consequently reduce intracellular
chloride concentration and susceptibility to depolarization upon opening of chloride
channels. Given the compelling link to MO25, it is worth investigating how the absence
of STRADA in PMSE might impact MO25 function, and particularly NKCC1 activation
and neuronal firing potential. Finally, it will be important to determine whether easily
accessible and generally well-tolerated loop diuretics might be able to impact neuronal
firing and treat seizures in PMSE patients.
To evaluate the effects of STRADA loss on NKCC1 activity and neuronal firing,
as well as the treatment potential of loop diuretics, we are establishing cultures of derived
PMSE patient and control neurons, in collaboration with Dr. Jack Parent at the University
of Michigan. PMSE patient and control fibroblasts were reprogrammed into pluripotent
lines through transduction of four transcription factors, including Oct4, Sox2, Klf4, and
c-Myc (137, 138). Induced pluripotent stem cells (iPSCs) originating from PMSE
patients and controls were established, then differentiated into Tuj1-positive PMSE
neurons (Figures 5.1 and 5.2). Importantly, this will allow single-cell recording in a
human neuronal line to determine if STRADA loss affects the firing potential of
individual neurons independently of network dynamics, as well as evaluation of
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treatment options, without requiring invasive procedures to obtain these cells from
patients.
mTOR Dysregulation, Neurodevelopmental Disease, and Epilepsy: Toward Effective
Therapy
mTOR signaling plays a critical role in corticogenesis. Tight regulation of this
cascade is essential to normal development, and disruption of this process can result in
myriad developmental disorders. Interestingly, loss of function mutations in mTORinhibitory genes such as TSC1 or TSC2, or gain of function mutations in mTOR
activators such as AKT3 result in aberrant brain development and intractable seizures (28,
29, 139). Since epilepsy in these patients is so often refractory to treatment with antiepileptic drugs, it has been suggested that directly targeting the mTOR pathway might
prove more effective (140, 141). Indeed, recent clinical trials have been promising. The
mTORC1 inhibitor rapamycin (sirolimus) has been shown to induce the regression of
astrocytomas on MRI in TSC patients, while cessation of treatment was associated with
mass regrowth until treatment was resumed (142). Additionally, rapamycin treatment has
been shown to reduce seizure frequency in TSC patients with otherwise medically
intractable epilepsy (143). Recently, treating TSC patients with the rapamycin analogue
everolimus was associated with reduction of subependymal giant cell astrocytoma
(SEGA) volume and seizure frequency (144).
PMSE is a rare genetic disorder, yet it can offer key insights into the role of
aberrant mTOR signaling in several more common neurodevelopmental disorders. We
propose that PMSE serves as an important model of mTOR-associated brain disease
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since all PMSE patients share the same deletion in STRADA and thus represent a
homogeneous study group, and since this is to date the only identified mTOR-associated
disorder resulting from a genetic homozygous deletion.
PMSE is disorder with 100% penetrance. All patients will develop intractable
seizures and cognitive decline, and no effective treatment strategies have yet been
reported. Based on our pre-clinical results demonstrating rescue of cell size and
migration defects with rapamycin treatment, we administered rapamycin (sirolimus) to 5
PMSE patients at the Clinic for Special Children in Lancaster, PA, in collaboration with
their physician Dr. Kevin Strauss. Rapamycin treatment was tolerated by all 5 patients
and no adverse events to necessitate cessation of the treatment were experienced (Table
5.1). Compared with historical PMSE controls (n=16, ages 7 months to 28 years), of
whom 100% currently experience ongoing and intractable seizures at least monthly, and
in many cases daily, rapamycin-treated patients experienced a profound decrease in
seizures, with only one child in the cohort experiencing one seizure, at a time of febrile
illness, during the most recent year of rapamycin therapy (61). Of note, Patient 1 in our
cohort has never had a seizure at age 8 months, whereas rapamycin-naïve PMSE patients
typically start to seize between 3 and 6 months of age. Patient 3, who was previously
burdened with 180 seizures per year, has been seizure free over the last year on
rapamycin. In both the historical control group and our rapamycin-treated cohort, the
Denver Developmental Screening Test II was used to measure psychomotor
development, and provisional developmental differences between the two groups were
noted in receptive language and social domains. Anecdotally, parents of PMSE children
report that those on rapamycin seem more interactive and more emotionally engaged than
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those not treated with the drug. Long-term effects will need to be evaluated in order to
make safe clinical recommendations, but promising early results suggest that targeting
mTORC1 signaling might be the key to effectively treating seizures and other disease
manifestations in these otherwise-intractable patients.
Through PMSE, we were able to model STRADA depletion and define the role of
STRADA and mTORC1 signaling in neuronal migration and brain development, as well
as characterize the effects of STRADA’s absence and consequently aberrant mTORC1
signaling in disrupted corticogenesis. Thus, we have added STRADA to the list of key
regulators of neuronal migration and mTOR signaling during cortical development. By
evaluating the rescue potential of rapamycin and p70S6Ki throughout our experiments,
we established pre-clinical precedent for targeting mTORC1 signaling as a therapeutic
strategy to treat PMSE as well as other mTOR-associated neurodevelopmental disorders.
Our promising early clinical data in the PMSE population suggests that pharmacological
mTOR inhibition could be a highly effective treatment strategy and a key to preventing
seizures and cognitive decline in these patients.
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Table 5.1. Clinical Summary of PMSE Patients Treated With Sirolimus
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*For patient <1 year of age, this column lists the number of seizures since birth.
†Developmental Quotient is defined as developmental age, determined by the Denver
Developmental Screening Test II, divided by chronological age. A score of 1.0
represents psychomotor development commensurate with age.
§Gross motor development of STRADA-deficient children is hindered by congenital
absence of anterior cruciate ligaments, which leads to recurrent knee dislocations and
typically precludes ambulation.
¶All STRADA-deficient patients are mute; we therefore determined separate
Developmental Quotients for expressive or "spoken" langauge and receptive or
"understood" language, the latter represented by pointing to or otherwise indicating
pictures, body parts, named family members, etc.
Abbreviations: AED, antiepileptic drug; CBZ, carbamazepine; GTC/SE, generalized
tonic-clonic seizure +/- status epilepticus;LEV, levetiracetam; OXC, oxcarbazepine; PB,
phenobarbital; TOP, topiramate.
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Figure 5.1. A colony of reprogrammed PMSE iPSCs. The colony sits atop a layer of
fibroblast feeder cells. Courtesy of Jack Parent, University of Michigan.
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Figure 5.2. PMSE derived neurons, with red fluorescence indicating Tuj1 staining for
neuronal maturity, and blue fluorescence indicating nuclear DNA. Courtesy of Jack
Parent, University of Michigan.
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